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1. Introduction 
1.1. Pancreatic Cancer 
1.1.1. Epidemiology 
Pancreatic cancer still is one of the tumor entities with the highest 
mortality rate. Less than 5% of the patients with pancreatic cancer 
survive more than five years (Hidalgo, 2010). According to the 
cancer statistics in 2013, there were approximately 43,920 new-
onset pancreatic cancer cases in the USA, with 37,290 deaths 
(Siegel et al., 2013). The most common histologic type of pancreatic 
cancer is pancreatic ductal adenocarcinoma (PDAC), representing 
95% of pancreatic tumors (Tanaka, 2015). Risk factors can be 
divided into two major groups, one consisting of a chronic 
inflammation due to chronic pancreatitis, tobacco smoking or 
alcohol, the other of diet factors such as hyperglycaemia, obesity 
and diabetes mellitus (Maisonneuve and Lowenfels, 2015).The 
poor prognosis results mainly from a late diagnosis and a lack of 
therapy approaches with curable intention. Since most patients do 
not develop any specific symptoms at early stages of the disease 
and there are moreover no reliable screening tests, metastases 
have often already occurred at the time point of diagnosis (Rao and 
Mohammed, 2015, Garrido-Laguna and Hidalgo, 2015).  
 
1.1.2. Established therapies 
The only available therapy with curative intention to date is the 
complete surgical resection. Nonetheless, patients undergoing 
surgical interventions have miserable prospects of long-term-
survival. 85% of operated patients develop locoregional 
recurrences or distant metastases over the course of time (Sutton 
and Abbott, 2014).  
Since surgery is associated with bad outcomes, almost all patients 
receive chemotherapeutics afterwards. Beyond application in an 
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adjuvant setting, cytotoxic drugs are furthermore applied in neo-
adjuvant settings as well as in palliative stages of disease (Garrido-
Laguna and Hidalgo, 2015). Whereas 5-fluorouracil (5-FU) had 
been the only beneficial agent for decades, it has been replaced by 
gemcitabine in the late 90s (Burris et al., 1997). Other 
chemotherapy based regimes, like FOLFIRINOX (5-FU, leucovorin, 
irinotecan, and oxaliplatin) and gemcitabine plus nab-Paclitaxel 
provide, if any, a few months improvement in survival (Conroy et 
al., 2011, Mohammed et al., 2014).  
Regarding the failure of chemotherapeutics in pancreatic cancer, 
several resistance mechanisms have been revealed. In particular, 
overexpression of certain drug efflux pumps (ABC transporter) and 
enzymes that cleave drugs like gemcitabine, specific genetic 
mutations as well as deregulation of key signaling pathways like the 
NF-κB and Notch pathway were shown causing chemo-resistance 
(Long et al., 2011). Constituting another big obstacle, 
chemotherapeutics have to overcome the distinctive hypoxic, acidic 
environment in pancreatic cancer that is characterized by an 
insufficient vascularization, thereby impairing drug delivery 
especially in the center of solid tumors (Long et al., 2011). 
Concerning the tumor environment, pancreatic cancer is typically 
pervaded by a dense desmoplastic tissue. Therein, extracellular 
matrix (ECM) proteins are produced that protect cancer cells from 
the induction of apoptosis by anticancer drugs (Miyamoto et al., 
2004). 
 
1.1.3. Molecular-targeted therapy 
With the growing understanding of molecular pathways involved in 
pancreatic cancer, new therapeutic targets have been identified. 
Erlotinib, an Epidermal Growth Factor Receptor tyrosine kinase 
inhibitor (EGFR-TKI), in combination with gemcitabine was 
approved by the U.S. Food and Drug Administration (FDA) for the 
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treatment of locally advanced and metastatic pancreatic cancer in 
2005, extending the median survival time from 5.91 to 6.21 months 
(Steins et al., 2014). The most common mutation in pancreatic 
cancer concerns KRAS, being present in 90% of tumor cells. This 
cornerstone of carcinogenesis in pancreatic cancer might provide a 
possible beneficial effect of ras inhibitors. Unfortunately,  several 
farnesyltransferase inhibitors which are involved in post-
translational modifications of ras proteins, failed to kill tumor cells 
successfully (Teague et al., 2015). Likewise, approaches inhibiting 
proteins downstream in the ras pathway, like MEK, were not 
successful (Garrido-Laguna and Hidalgo, 2015). Eventually, a 
combination of gemcitabine with the anti-VEGF monoclonal 
antibody Bevacizumab did not yield promising results in a 
randomized phase III study either (Kindler et al., 2010). 
Further innovative approaches are being evaluated at the moment, 
including the CTLA-4 inhibitor Ipilimumab, tumor vaccines and 
tumor specific antibodies (Teague et al., 2015). 
This short overview about present strategies to treat pancreatic 
cancer outlines established therapies as well as new approaches 
being currently tested, in sum demonstrating the urgent demand for 
novel effective therapeutic strategies in pancreatic cancer. 
 
1.2. Oncolytic virotherapy 
The term oncolytic virotherapy describes the use of viruses as 
anticancer agents. Due to their naturally occurring or genetically 
modified ability to selectively replicate in and afterwards lyse tumor 
cells, healthy tissue remains unaffected. 
 
1.2.1. History of discovery and research 
Already in the mid-1800s, case reports that described tumor 
regressions of cancer patients suffering from virus infections at the 
same time, emerged (Kelly and Russell, 2007). For this reason 
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George Dock assumed that infections can be utilized in order to 
cure cancer patients (Hammill et al., 2010). In line with this, 
clinicians attempted to conquer cancer with the aid of body fluids 
obtained from virus infected people (Southam, 1960). Similar 
observations of tumor regression were made following anti-rabies 
vaccination (Moore, 1954) (Fig. 1). Initially, wild-type viruses were 
used and consequently lots of infectious complications occurred. 
After having exploited recombined DNA technology to create 
attenuated viruses, virotherapy has finally made its breakthrough in 
becoming a well-respected alternative as compared to other ant-
cancer drugs (Hammill et al., 2010). 
After having gained more and more knowledge about different 
tumor entities and their pathological features, it became evident that 
haematological malignancies are especially susceptible to virus-
mediated oncolysis. In this regard, infection with measles virus 
induced remission of Hodgkins´s Lymphoma (Taqi et al., 1981) and 
Burkitt´s Lymphoma (Bluming and Ziegler, 1971) (Fig.1). The 
astonishing response rate of these malignancies can be ascribed to 
the concomitant immune suppression preventing systemic 
elimination of viruses in the blood stream (Liu et al., 2007). 
Figure 1: Timeline of the clinical history of virotherapy; taken from (Liu et al., 
2007) 
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Moreover, oncolytic viruses have shown promising effectivity in the 
treatment of solid tumors. Since many in vitro studies had provided 
new insights into mechanisms of action, several clinical studies 
have been performed. In this context, different oncolytic viruses 
have been proven to be efficient in the treatment of sarcomas 
(Lettieri et al., 2012), pancreatic cancer (Wennier et al., 2011) and 
glioblastoma multiforme (Wollmann et al., 2012). 
 
1.2.2. Mechanism of action 
Since viruses are not capable of replicating themselves like living 
organisms, they have to exploit the synthetic machinery of their host 
cells. After having produced a great number of new virions, host 
cells undergo cell lysis, subsequently releasing viruses, which in 
turn spread from cell to cell, thereby infecting the nearby tissue and 
proceeding the infection in a self-amplified manner (Giorda and 
Hebert, 2013). 
As commonly known, each virus yields a distinct tropism for specific 
cells. Fortunately, several viruses naturally exhibit a selective 
tropism for different cancer cells, e.g. parvovirus, reovirus, 
newcastle disease virus, mumps virus and moloney leukemia virus. 
Other viruses were shown to be well suited for genetic modifications 
(Russell et al., 2012)(Fig. 1). Typical strategies are engineering 
viruses to target specific surface proteins as entry receptors or to 
express their genes under the control of tumor specific promoters 
(Russell et al., 2012). Another reason for cancer cell tropism is a 
lack in the antiviral response, being initiated by type I Interferon 
signaling. Whereas normal cells manage to efficiently eliminate 
invaded viruses, approximately 80% of cancer cells exhibit 
mutations in this pathway (Stojdl et al., 2003). More precisely, 
healthy cells detect non-self-associated molecular patterns 
(PAMPs) by means of pattern recognitions receptors (PRRs). As a 
consequence, viral nucleic acid or specific viral surface proteins are 
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identified, resulting in the induction of type I IFN production in 
infected cells. These cells as well as surrounding cells establish an 
antiviral state due to binding of IFN-β to its receptor. Therefore, they 
express antiviral enzymes, shut down their protein synthesis 
machinery in order to restrict viral replication and express 
additionally MHC-I proteins, whereby facilitating immune cells the 
detection of infected cells (Diamond and Farzan, 2013) (Fig. 2). In 
contrast to healthy cells, cancer cells do not express genes which 
encode for pathogen-receptors and antiviral effectors like RNAses 
and GTPases (Sen, 2001), making them an easy target for oncolytic 
viruses. Beyond that, cancer cells feature a resistance to apoptosis 
as well as to the ability of shutting down gene expression and 
translation which are naturally strategies to encounter virus 
infections (Russell et al., 2012). 
 
 
 
Figure 2: Type I IFN signaling following virus infection 
After virus infection, cellular pathogen sensors (MDA5 and RIG-I) detect invaded 
viruses through their nucleic acid which is followed by phosphorylation of IRF3 
and consequently the production of IFN-β (1-4). IFN-β takes effect in autocrine 
as well as paracrine manner, whereby binding to its receptor runs downstream 
JAK/STAT signaling (5-7). The complex of STAT 1, STAT 2 and IRF 9 initiates 
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the expression of IFN-stimulated genes (ISGs) (8); taken from Hall and al. (Hall 
and Rosen, 2010)  
 
Furthermore, viruses display a perfect vector for delivering genes to 
cancer cells in order to potentiate the efficiency of oncolytic viro-
therapy. Thus, genomes of different viruses can be modified by 
adding genes encoding for proteins that both directly and indirectly 
enhance their therapeutic effect. Typical strategies are inserting 
pro-apoptotic proteins like TRAIL (Tumor Necrosis Factor Related 
Apoptosis Inducing Ligand) or pro-drug convertases like 
supercytosine deaminase (Kasman et al., 2012, Lampe et al., 
2013). 
 
1.2.3. Oncolytic immunotherapy 
The common way of identification and combat against mutated 
cells, mainly executed by antigen-presenting cells (APCs) and NK 
cells, is avoided through several mechanisms in tumors, evolved 
during the process of tumorigenesis. Important steps being 
frequently impaired are DC maturation, T cell extravasation by 
downregulation of adhesion molecules, overexpression of inhibitory 
receptors like PD-L1 and eventually by the downregulation of 
identification receptors such as MHC-I molecules (Zamarin and 
Wolchok, 2014). These barriers eventuate in an 
immunosuppressive tumor-microenvironment.  
To further emphasize these observations, the extent of T cell 
infiltration into the tumor bed seems to be a good prognostic marker 
for the outcome of patients suffering from different cancer types and 
is momentary evaluated for embedding into the new “immunoscore” 
classification of cancers (Galon et al., 2012, Fridman et al., 2012).  
Astonishingly, OVs were found being able to overcome those 
barriers. In this way, they are capable of changing the tumor 
microenvironment regarding the cytokine profile as well as the 
amount of expressed immunosuppressive receptors, thereby 
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attracting more and more immune cells to the tumor bed. 
Considering oncolysis, plenty of tumor associated antigens (TAAs) 
are released which are in turn detected by dendritic cells, following 
antigen presentation to lymphocytes and initiation of an anti-tumor 
immune response. Cancer cells can be additionally easier 
recognized due to upregulation of MHC-I molecules (Prestwich et 
al., 2009, Melcher et al., 2011, Woller et al., 2014, Lichty et al., 
2014, Zamarin and Wolchok, 2014)(Fig. 3). These virus-induced 
processes enable a well-coordinated combat against tumors and 
therefore prompted researchers to change the classical term of 
“virotherapy” to “oncolytic immunotherapy” (Coffin, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The schematic depiction shows the impact of virus infection on tumor cells, the 
cancer microenvironment and on immune cells. Oncolytic viruses induce 
expression of MHC-I molecules as well as costimulatory receptors in tumor cells. 
Through oncolysis, tumor- associated-antigens (TAAs) and damage-associated-
molecular patterns (DAMPs) are exposed. Finally, this leads to an infiltration of 
immune cells in tumor tissue. Taken from (Zamarin and Wolchok, 2014). 
 
1.2.4. Advantages and disadvantages 
In contrast to established cancer therapeutics which affect the entire 
organism and are therefore associated with partly severe side 
effects like lymphopenia or anemia oncolytic viruses show little 
adverse drug reactions due to their relative cancer selectivity 
(Bourke et al., 2011). Moreover, only a single dose is required for 
eliciting amazing effects due to their self-amplification through 
Figure 3: Principles of oncolytic immunotherapy 
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replication and propagation (Russell et al., 2014). Another beneficial 
aspect of oncolytic viruses is their ability to target systemic 
metastases and most notably cancer stem cells which are regarded 
as being responsible for tumor relapse and chemo-resistance since 
they are capable of self-renewing after having been treated with 
cytotoxic drugs (Smith et al., 2014).  
Beyond the direct impact on cancer cells, the impact on the tumor 
environment has to be also recognized. Tumor cells are normally 
embedded in a very hypoxic and acidic microenvironment, as they 
are supplied by blood only through leaky and thin-walled blood 
vessels. Keeping this in mind, oncolytic viruses are capable of 
inhibiting blood flow to the tumor side, thereby inducing ischemic 
cell death. The underlying mechanism is not totally understood yet 
but a reduction in blood vessel density, a destruction of vasculature 
that cause haemorrhage into tumor tissue as well as virus-induced 
neutrophils-promoted clot formation have been observed (Bourke 
et al., 2011, Breitbach et al., 2007, Huszthy et al., 2010, Breitbach 
et al., 2011).  
A big problem in establishing new therapeutic strategies, especially 
in the treatment of cancer, is based on adverse reactions that even 
could occur after a long period. In respect thereof, the safety of 
oncolytic viruses has been proven in over 500 treated patients 
during the last 20 years of clinical studies. During this time, only one 
OV-treated patient died due to rapid tumor lysis. Typical side effects 
are flu like symptoms and in some cases thrombocytopenia and 
vascular leakage caused by fast intravenous injection (Liu et al., 
2007). 
Nonetheless, oncolytic viruses are faced with several obstacles on 
their way conquering cancer. When administered intravenously, 
viruses are eliminated in the liver, bound by immune cells or 
inactivated by pre-existing antibodies and complement factors due 
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to a prior infection or vaccination. As a consequence, OVs are 
impaired in their effectivity (Breitbach et al., 2007, Chiocca, 2008). 
In order to circumvent systemic removal, direct injection into the 
tumor mass has to be considered as an alternative. But since 
oncolytic viruses should serve as systemic therapeutics with 
curative intention, both the primary tumor and metastases should 
be attacked. Therefore, researchers were prompted by the idea to 
combine oncolytic viruses with supporting drugs in order to enhance 
oncolytic effectivity. This point will be discussed below.  
 
1.3. Measles virus 
1.3.1. Common features 
Measles virus (MeV) belongs to the genus Morbilliviruses of the 
family Paramyxoviridae. Further members are the rinderpest virus 
(RPV) and the canine distemper virus (CDV).  
 
a) schematic image of an entire virion; b) structure of measles virus genome; c) 
representation of a measles virus life cycle. Figure from Moss et al. (Moss and 
Griffin, 2006)  
 
Figure 4: Typical features of measles viruses 
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They are enveloped viruses with a non-segmented, negative-strand 
RNA genome, containing six different genes. Due to post-
translational modifications eight proteins are translated and 
consequently form the entire virion (Fig. 4): the nucleocapsid (N), 
phospho- (P), matrix (M), fusion (F), haemagglutinin (H) and large 
(L) proteins (Yanagi et al., 2006). The F and H proteins are key 
factors for penetrating host cells. To do so, they interact with CD46, 
which is expressed on all nucleated human cells, and SLAM 
(signaling lymphocyte activation molecule), which is only expressed 
in immune cells, thereby inducing membrane fusion and virus 
uptake. After viral RNA has been transcribed, the F and H proteins 
are present on infected cells causing cell to cell fusion and 
subsequently formation of multinucleated giant cells. The M protein 
which is located in the inner surface of the envelope is involved in 
virus budding and transcription regulation. The nucleocapsid 
consists of the N, L and P proteins, the latter can undergo 
posttranslational modifications, originating the non-structural C and 
V proteins (Yanagi et al., 2006, Sato et al., 2012, Msaouel et al., 
2012). These proteins were shown to impair the innate immune 
response by antagonizing type I IFN signaling and additionally 
enhance autophagic flux in host cells (Richetta et al., 2013). 
Regarding measles viruses as human pathogens, they may cause 
fever, cough and coryza, as well as respiratory and gastrointestinal 
diseases. In the worst scenario infected people may develop fatal 
lung and brain complications (Sato et al., 2012, Msaouel et al., 
2013). 
 
1.3.2. Measles as an oncolytic virus 
The most striking benefit of using measles as an oncolytic agent 
can be deduced from the experience that has been gained in 
vaccination programs for many years. In conclusion, safety as well 
as effectivity could be prosperously proven during the immunization 
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of over one billion recipients (Lievano et al., 2012, Hutzen B, 2015). 
Indeed, progenies from the attenuated virus vaccine (Edmonston 
strain) were found to have the ability to of destroying cancer cells 
both in vitro and in vivo (Guillerme et al., 2013). Since MeV-Edm 
serves as a vaccine, it has to be apprehended that the application 
to almost an entire population is connected with limitations in the 
administration of measles as oncolytic viruses due to the induced 
immunity, most prominently represented by neutralizing antibodies. 
Viruses are a potential source of danger for the population due to 
their mutability, pathogenicity and transmissibility. However, there 
has never been a report on a reversion to wild-type measles 
(Russell and Peng, 2009). 
Whereas wild-type measles virus typically infects lymphocytes via 
SLAM, laboratory derivatives obtained from the Edmonston strain, 
prefer CD46 for membrane fusion and virus uptake, since they have 
acquired a relative entry receptor tropism as a result of changing 
amino acid 481 in the H-attachment protein from asparagine to 
tyrosine (Nielsen et al., 2001). 
CD46 physiologically inactivates complement factors C3b and C4b, 
thus shielding cells from autologous complement destruction 
(Msaouel et al., 2013). For this reason, it is supposed that CD46 is 
frequently overexpressed in cancer cells (Fishelson et al., 2003), 
leading to the avoidance of cell lysis through complement activation 
(Guillerme et al., 2013) but therefore making them an easy selective 
target for MeV. Remarkably, the cytopathic effect (CPE) induced by 
MeV correlates with the CD46 density on infected cells (Anderson 
et al., 2004).  
The typical pathogenic feature of infected cells is represented by 
the formation of syncytia carried out by the F and H proteins. 
Thereby neighboring cells are forced to form multinucleated giant 
cells, in this way offering measles virus a platform for efficient 
replication (Guillerme et al., 2013, Takeuchi et al., 2003). Since 
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even uninfected cancer cells are targeted to form syncytia by 
infected cells, MeV exhibits a remarkable bystander effect (Msaouel 
et al., 2012).  
Regarding oncolytic selectivity, healthy cells are not affected by the 
formation of syncytia, since they ordinarily do not exceed a minimal 
threshold of CD 46 density which is required for virus-induced cell 
to cell fusion (Anderson et al., 2004, Russell and Peng, 2009).  
In summary, MeV is well suited to conquer cancer cells due to its 
relative selectivity for CD46 receptor, which is expressed with a high 
density on cancer cells. In addition, the ability of initiating cell to cell 
fusion, including neighboring uninfected cancer cells offers the 
additional benefit of inducing a bystander effect (Hutzen B, 2015). 
Hence, these characteristics delimit and favor them from other OVs 
and. In this context, another benefit compared to several other 
virotherapeutics, is their RNA genome. In contrast to DNA viruses 
such as adenovirus or herpes simplex virus, treatment with MeV is 
not associated with the possibility of insertional mutagenesis (White 
et al., 2014). 
 
1.3.3. Genetical engineering of oncolytic measles virus 
Measles viruses as many other oncolytic viruses display a well 
suited vector for introducing genes that enhance their therapeutic 
effectivity. Those genetic modifications can be grouped due to their 
effect in those for monitoring, increase in cancer selectivity, arming 
and immune-modulatory functions (Fig. 5). 
In this dissertation, measles virus encoding for green fluorescent 
protein (GFP) was used (Duprex et al., 1999), since it can be easily 
visualized by employing fluorescence microscopes (Hutzen B, 
2015). In order to obtain a maximal transcription rate of GFP, the 
gene was inserted into the 3´end of measles genome upstream of 
the N gene (Duprex and Rima, 2002). 
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Figure 5: Possibilities for genetically engineering of measles virus genome 
  Taken from (Hutzen B, 2015) 
 
Considering oncolytic virotherapy of patients suffering from 
pancreatic cancer, MeV was made selective for pancreatic cancer 
cells by changing the tropism from CD46 to prostate stem cell 
antigen (PSCA) which is not expressed on healthy tissue but 
numerously on pancreatic adenocarcinoma (Bossow et al., 2011).  
As stated above, the wild-type P protein impairs the host cell anti-
viral immune response. Since the Edm-Strain has lost its P protein-
function, MeV was equipped with the wild-type P gene in order to 
circumvent production of type I IFN by infected tumor cells, thereby 
facilitating virus replication and spread. Due to concerns of 
enhanced pathogenicity, no clinical evaluation has been preceded 
although in vitro experiments as well as animal studies revealed 
beneficial results (Haralambieva et al., 2007, Hutzen B, 2015). 
Following the present trend of exploiting the antitumor immune 
response in order to contain and delay tumor progression and 
metastasation in advanced tumor stages, MeV was already 
endowed with transgenes, encoding for GM-CSF and antibodies 
against CTLA-4 as well as PD-L1 resulting in encouraging findings 
(Engeland et al., 2014, Grossardt et al., 2013). 
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To summarize the possibility of genetically modifying the MeV 
genome, there is a broad spectrum of approaches which enables a 
very specific targeting of distinct cancer types in clinical use. 
 
1.3.4. Clinical trials 
Several measles strains have been already tested in clinical 
practice to be safe and efficient. The first clinical trial that 
investigated a derivate from the Edmonston-Zagreb strain, was 
conducted in 2005, examining its therapeutic potential in five 
patients with cutaneous T-Cell Lymphoma (CTCL). Simultaneously, 
IFN-α was administered in order to avoid systemic complications 
due to virus infection. Tumor regression could be observed in 60% 
of treated patients and even more remarkably, distant lesions 
showed regression (Heinzerling et al., 2005). Since then, more 
clinical studies were performed and are still ongoing, respectively 
(Pol et al., 2014). Notably, two patients suffering from Multiple 
Myeloma, who were pretreated with several established 
chemotherapeutics as well as immunotherapeutics, a complete 
durable remission was recently achieved by a single injection of a 
specific measles virus (MeV-NIS) (Russell et al., 2014). 
 
 
1.4. Histone deacetylase inhibitors 
1.4.1. Histone deacetylases and their physiological function 
Cells and even cell nucleuses are only a few µm in diameter but still 
have to contain the entire human genetic information which is 
encoded in the DNA. Due to its length of at least two meters, the 
double-helix has to be condensed to a very small space. Therefore, 
it is wrapped around specific proteins, called histones. Those 
display lots of positive charged amino acids (lysine residues), 
attracting negatively charged DNA and thus forming a very tight 
formation. The dynamic interplay of acetylation and deacetylation of 
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lysine residues, as well as further modifications like methylation, 
ubiqutination and phosphorylation enable a coordinated regulation 
of gene expression (Abend and Kehat, 2015, Kouzarides, 2007). 
Mechanistically, deacetylation of lysine residues allows the 
negatively- charged DNA to bind stronger to histones, thereby 
compacting chromatin structure, impairing and inhibiting gene 
transcription (Khan and La Thangue, 2012).  
Enzymes being involved in this process are histone deacetylases 
(HDAC) and histone acyltransferases (HAT) (Abend and Kehat, 
2015). Here, we will just focus on HDAC, since they are the target 
structure of the inhibitor employed in this dissertation. This enzyme 
family consists of 18 different members which are grouped in four 
classes due to their sequence homology to Saccharomyces 
cerevisiae (Abend and Kehat, 2015). Regarding the different 
classes, class I, II and IV are Zn+-dependent whereas class III 
inhibitors, also named sirtuins, are NAD+-dependent. In relation to 
this classification, more precise investigations indicate that each 
class of HDAC is involved in the execution of specific tasks 
(Dokmanovic et al., 2007). Class I enzymes are involved in cell 
survival and proliferation, while class II accomplish tissue specific 
functions, for instance expression of HIF-α, induction of 
vascularisation and chondrocyte differentiation. Class IV HDACs 
(only HDAC 8) are considered to be a combination of class I and II, 
as they yield typical functional and structural features of both 
(Dokmanovic et al., 2007). 
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Figure 6: Interplay of HDACi and HATs 
Processes which are regulated through acetylation and deacetylation of different 
lysine residues catalysed by HATs and HDACs (Yang and Seto, 2007) 
 
Considering acetylation as a typical co- and post-translational 
modification of proteins, almost 85% of all cellular proteins are 
involved in this process (Polevoda and Sherman, 2000). Due to its 
unique implementation in cell signaling, several tasks, including 
enzymatic activity as well as stability, DNA binding, protein-protein 
interaction and peptide-receptor recognition are executed by this 
crucial process (Polevoda and Sherman, 2002). But not all 
acetylating enzymes are suitable targets for HDACi, as they are 
only capable of deacetylating proteins on ƹ-amino acids of lysine 
residues (Glozak et al., 2005). Nonetheless, beyond their ability to 
deacetylate histones, more and more non-histone proteins have 
been learned being substrates of HDACs. For this reason the terms 
lysine deacetylases (KDACs) and protein deacetylases (PDACs) 
have been established (Rajendran et al., 2011). Important 
substrates are transcription factors such as NF-κB or p53 as well as 
STAT proteins which are responsible for mediating signals of 
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proliferation, survival and immune response (Spange et al., 2009). 
After having been deacetylated, those proteins either bind stronger 
to the DNA, thereby enhancing transcription rate, or they forfeit their 
affinity to DNA with the result of decreasing gene transcription (Park 
et al., 2015). Additionally, HDAC6 which is localized in the 
cytoplasm seems to possess an important function in aggresome-
formation and may therefore ensure cell viability if cells are exposed 
to cellular stress induced by misfolded proteins (Kawaguchi et al., 
2003).  
Since HDACs are essential for an adequate balance between 
apoptosis and proliferation, several of them were found being 
overexpressed in different tumor entities (Dokmanovic et al., 2007, 
Buchwald et al., 2009, Glozak and Seto, 2007). With respect to the 
topic of this dissertation, an enhanced expression of HDAC 1, 2 and 
7 was detected in samples of patients suffering from pancreatic 
cancer (Fig. 7), supporting tumor maintenance and further 
progression (Schneider et al., 2010). Presumably, a decreased 
expression of the cyclin-dependent kinase inhibitor p21 is one of the 
best investigated changes due to overactivity of HDACs, in this way 
imitating a loss of function mutation and subsequently preventing 
the cell from initiating cell cycle arrest (Glozak and Seto, 2007). 
Another typical feature of epigenetic changes in tumor cells is the 
hypoacetylation of histone H4, indicating an increased HDAC 
activity (Fraga et al., 2005). 
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Figure 7: Impact of HDAC overactivity in pancreatic adenocarcioma 
Left: impaired expression of E-cadherin facilitates EMT (epithelial-mesechymal transition) 
and thereby the process of metastasation; middle: HDAC promote an imbalance between 
anti- and pro-apoptotic proteins, causing apoptosis as well as therapeutic resistance; right: 
Acceleration of cell cycle, increasing proliferation; figure based on (Schneider et al., 2010) 
 
Taken together, overexpression and / or an enhanced activity of 
HDACs could be regarded as one major cornerstone for both 
tumorigenesis and tumor progression and thus display a promising 
target for anticancer therapy. 
 
1.4.2. Histone deacetylase inhibitors: impact on cancer and immune cells 
Back in 1977, Riggs and colleagues already observed that n-
Butyrate cause hyperacetylation of histone proteins accompanied 
by alterations of gene expression (Riggs et al., 1977). The 
underlying mechanism of inhibiting enzymes endued with the ability 
of deacetylating proteins was discovered one year later (Sealy and 
Chalkley, 1978, Boffa et al., 1978). 
HDAC inhibitors (HDACi) are solely capable of inhibiting enzymes 
containing zinc in their catalytic centre, thus not affecting the NAD+-
dependent sirtuins (class III HDACs). Because of their different 
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chemical structure, they are divided into four different groups: 
hydroxamates, cyclic peptides, aliphatic acids, and benzamides. 
Another differentiation is based on their selectivity. On the one 
hand, there are pan-inhibitors including panobinostat, belinostat, 
trichostatin A, vorinostat and resminostat. One the other hand, there 
are selective ones like valproate (VPA), inhibiting only class I and 
IIa HDACs or romedepsin, being class I selective (Khan and La 
Thangue, 2012).  
Their anticancer effect is based on their ability of inducing cell death 
and preventing further tumor progression by intervening in several 
different signaling pathways. In this manner, they function as cell 
cycle inhibitors, cause an accumulation of reactive oxygen species 
(ROS), induce apoptosis via both the extrinsic and the intrinsic 
apoptotic pathway and furthermore it is believed that they act like 
taxanes by impairing mitosis (Khan and La Thangue, 2012). Despite 
their capability of immediately inducing cell death, they were shown 
to inhibit tumor angiogenesis by suppressing transcription of HIF-α 
and VEGF, hence stopping the supply of nutrients and oxygen 
followed by cell necrosis and / or apoptosis, respectively (Khan and 
La Thangue, 2012). In addition, they may preclude cells from 
metastasizing by impairing gene transcription of matrix 
metalloproteinases (MMP) which are regarded as being involved in 
intravasation as one of the first steps of metastasation (Bolden et 
al., 2006, Deryugina and Quigley, 2015). Like oncolytic 
virotherapeutics, the most striking and valuable benefit of HDACi 
toward other classical cytotoxic drugs is equally based on their 
relative tumor selectivity (Bolden et al., 2006). 
Beyond their direct effect on cancer cells, HDACi are also relevant 
due to their impact on the immune system. This effect is carried out 
in two different ways. On the one hand, HDACi are capable of 
enhancing MHC-I expression as well as the expression of co-
stimulatory / adhesion molecules such as CD40, CD80, CD86 both 
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on cancer cells and antigen-presenting cells (APCs), thereby 
facilitating especially cytotoxic T cells the detection and 
subsequently the elimination of those mutated cells. Helper T cells 
in turn initiate a powerful systemic anti-tumor-immune response 
(Bolden et al., 2006, Setiadi et al., 2008). Further important genes 
were found being HDACi-related upregulated with an emphasis on 
tumor specific antigens (TAAs) (Kroesen et al., 2014). On the other 
hand, HDACi both directly and indirectly alter the cytokine secretion 
of immune cells, affecting most of all type I IFN signaling but also 
the production of different interleukins and pro-tumorigenic 
cytokines (Bolden et al., 2006, Kroesen et al., 2014). 
Regarding the impact on NK cells as important players in the 
recognition and eradication of cancer cells, studies have yielded 
contradictory findings so far (Moretta et al., 2005). It was revealed 
both an upregulation and a downregulation of ligands on tumor cells 
as well as NK cells themselves. Although HDACi treatment leads to 
a positive change in NK cell activation through signals from tumor 
cells, it was ascertained that their production of cytotoxic proteins 
like granzyme b and granule release in sum decreases (Ogbomo et 
al., 2007, Alvarez-Breckenridge et al., 2012, Kroesen et al., 2014). 
In conclusion, the diverging in vitro results with regard to NK cells 
do not seem to be transmittable to the impact on an entire living 
organism and thus, has to be studied in vivo in more detail. 
 
1.4.3. Clinical application of HDACi 
Since HDACi had revealed their potential of killing tumor cells 
efficiently in vitro, they have been investigated in clinical trials, 
showing promising results, especially in the treatment of 
hematological malignancies (Mottamal et al., 2015). Therefore, 
three HDACi were approved by the FDA to date: Vorinostat for the 
treatment of patients with cutaneous T-Cell Lymphoma (CTCL), 
romedipsin for application to patients with peripheral T-cell 
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lymphoma (PTCL) and third, belinostat for treatment of patients with 
relapsed or refractory PTCL. Beyond their positive effect on 
neoplasias concerning blood cells, they have already shown 
encouraging results in the treatment of solid tumors and still more 
studies are being conducted at the moment (Mottamal et al., 2015). 
Nonetheless, application in combination with other drugs seems to 
be even more promising (Thurn et al., 2011). Thus, HDACi have 
been combined with classical chemotherapeutics, radiotherapy and 
hormone therapies eliciting synergistic effects regarding both the 
induction of cell death and the overcoming of drug resistances (Park 
et al., 2015).  
With respect to potentially occurring side effects, hyponatremia, 
neutropenia, anemia, diarrhea and fatigue were observed in clinical 
trials so far. Nonetheless, HDACi are altogether well tolerated 
(Koutsounas et al., 2013, Mottamal et al., 2015). 
 
1.4.4. Resminostat 
Similar to vorinostat resminostat is a hydroxamic acid-based HDACi 
which is an orally administered pan-inhibitor of class I and II HDAC 
enzymes (Brunetto et al., 2013). It exhibits the typical effects of 
HDACi. In this manner, treatment with high doses induces potently 
apoptosis whereas the application of lower doses leads to cell cycle 
arrest (Mandl-Weber et al., 2010). Concerning the tolerability of 
resminostat, a phase I study, investigating pharmacokinetics and 
pharmacodynamics clearly demonstrated that the drug is well 
tolerated. No other adverse reactions than those which have 
already been observed after treatment with HDACi in general, have 
been occurred (Brunetto et al., 2013). To further determine the 
potential of resminostat, several trials are being performed at the 
moment investigating the therapeutic effect in patients with 
advanced stage HCC (NCT00943449), patients suffering from 
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refractory Hodgkin’s lymphoma (NCT01037478), and patients with 
advanced colorectal cancers (NCT01277406). 
 
1.5. The epi-virotherapeutic approach – state of research 
1.5.1. Rationale 
As stressed above, oncolytic viruses are faced with different 
obstacles on their way conquering cancer, particularly, decreases 
in viral receptor expression (Li et al., 1999, Haviv et al., 2002, Kim 
et al., 2002), activation of intracellular tumor defense against viral 
infection (Berchtold et al., 2013, Escobar-Zarate et al., 2013) as well 
as virus clearance by the host cell immune system (Chiocca, 2008). 
These observations prompted researchers to look for possible 
supporting agents. Lots of trials have already investigated the effect 
of a combination between OV and classical chemotherapeutics 
(reviewed in (Fillat et al., 2014)). In this way, several different 
combination settings could reveal promising effects, especially 
emphasizing that there are no cross-resistances between OV and 
chemotherapeutics (Cripe et al., 2009). But due to potentially 
occurring severe adverse effects, cytotoxic agents should be 
preferably replaced by drugs that are better tolerable. 
Implementing the epi-virotherapeutic approach, represented by a 
combination between HDACi and OV, encouraging results have 
been achieved both in vitro and in vivo. The underlying mechanisms 
could be partly elucidated revealing several synergistic working 
points while being relatively selective to tumor tissue (MacTavish et 
al., 2010, Nguyen et al., 2010, Ruf et al., 2015) (Fig. 8). 
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Figure 8: Virus-induced oncolysis augmented by histone deacetylase inhibitors 
(HDACi) 
Following receptor binding (1), oncolytic viruses OVs infect tumor cells. Then, host cell 
ribosomes are occupied with translation of viral RNA into viral structural/functional proteins 
(2), resulting in generation of numerous progeny viral particles per single host tumor cell. 
This enormous replicative process ends up in complete exhaustion of host tumor cells, 
inescapably leading to tumor cell disintegration, i.e., viral oncolysis. Thereby, not only 
newly produced viral particles are released (3), but also tumor-associated antigens (TAAs) 
and damage-associated molecular pattern molecules (DAMPs), which are detected by 
antigen-presenting cells (APCs) (4) (Kaufman et al., 2015). Concurrently, OV infection 
induces production of pro-inflammatory, immune cell-attracting cytokines, which also exert 
potent antitumor activities (Prestwich et al., 2009). Furthermore, OV infections upregulate 
MHC-I expression on tumor cells (Gujar et al., 2013). Altogether, APC activation, 
production of antitumor cytokines and upregulation of antigen-presenting receptors are 
assumed to initiate a powerful T cell-mediated antitumor immune response (5) (Moehler 
et al., 2005, Kaufman et al., 2015). Notably, all these steps of the viral oncolytic cycle (1-
5) can be influenced by histone deacetylase inhibitors (HDACi): first of all, HDACi can 
upregulate expression of viral entry receptors on tumor cells leading to increased rates of 
tumor cell infection by OVs (1) (Wunder et al., 2013, Kasman et al., 2012, Nguyen et al., 
2010). Further, translocation of OV genomes, i.e., post-entry shuttling to the nucleus via 
microtubules (6) can be increased by HDACi (Nakashima et al., 2015a). Next, expression 
of viral genes can be augmented by HDACi in tumor cells (Nakashima et al., 2015b, Otsuki 
et al., 2008, Nakashima et al., 2015a). HDACi-enhanced tumor cell autophagy (7) can 
result in increased OV-mediated oncolysis and enhanced induction of tumor cell apoptosis 
(Shulak et al., 2014). Remarkably, HDACi were also found to be able to dampen antiviral 
IFN responses being characteristic for OV-resistant tumor cells (8) (Berchtold et al., 2013, 
Escobar-Zarate et al., 2013), thereby significantly facilitating OV replication and spread 
(Nguyen et al., 2010, Ruf et al., 2015, Otsuki et al., 2008, Nguyen et al., 2008). In terms 
of boosting immune cell-mediated antitumor response, HDACi can raise the levels of 
cytokines being supportive for the functional development of tumor antigen-specific CD8+ 
T cells (5) (Bridle et al., 2013). Beyond that, HDACi can also inhibit T- and NK cell-
mediated antiviral responses, supporting an unimpaired OV replication and propagation in 
tumor cells (Bridle et al., 2013, Alvarez-Breckenridge et al., 2012). As HDACi can also 
cause upregulation of MHC-I molecules, co stimulatory receptors as well as TAAs (9) 
(Bolden et al., 2006, Kroesen et al., 2014, Setiadi et al., 2008), it is tempting to speculate 
that combined epi(HDACi)-virotherapeutic approaches might further amplify the 
magnitude of antitumor immune response. Taken together, OV-induced oncolysis can be 
Introduction 
 
- 30 - 
 
augmented by HDACi in many steps and on numerous levels of the interaction between 
host tumor cells and OVs.” (Ellerhoff et al., 2016) 
 
 
1.5.2. Overview over synergistic working points 
Although most cancer cells exhibit defects in their antiviral immune 
response, there are still cancer cells, being equipped with an intact 
or even reinforced response to invaders, most commonly due to 
mutations in the IFN-pathway (Escobar-Zarate et al., 2013, Stojdl et 
al., 2003). For instance, an enhanced expression of retinoic acid 
inducible gene I (RIG-I) and interferon-induced protein with 
tetratricopeptide repeats 1 (IFIT1) could be attributed to a 
resistance of different sarcoma cell lines against MeV-SCD 
(Berchtold et al., 2013). Both represent antiviral effector proteins 
which detect and subsequently initiate the elimination of invaded 
viruses and their expression is induced by IFN-signaling in order to 
detect and eliminate viruses (Schoggins and Rice, 2011). 
Since HDAC interact with enhancers of IFN-genes and are 
moreover involved in the expression of interferon-stimulated-genes 
(ISGs) (Nusinzon and Horvath, 2006, Kadota and Nagata, 2011), 
HDACi are indeed capable of damping the host cell IFN-response, 
thereby enhancing virus-mediated replication and spread through 
tumor tissue (Vlasakova et al., 2007) (Fig. 8). Remarkably, cells 
which had been primarily resistant toward OVs could be made 
susceptible due to HDACi treatment (Nguyen et al., 2008, 
MacTavish et al., 2010).  
Autophagy is a catabolic process which describes the degradation 
of cellular components and recycling in lysosomes in order to 
maintain a cellular homeostasis. Furthermore it serves as a 
response to stress, lack of nutrients, hypoxia, as well as for the 
elimination of intracellular pathogens like bacteria and viruses 
(Murrow and Debnath, 2013). Several studies revealed that some 
viruses profit from the pharmacological induction of this pathway, 
thereby enhancing their anticancer activity (Meng et al., 2013). In 
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this context, vorinostat in combination with vesicular stomatitis virus 
(VSV) led to an enhanced oncolytic effect via an upregulation of 
autophagy stimulated genes (ATG101, ATG7, and GABARAPL1) 
(Shulak et al., 2014).  
As another important synergistic working point, an enhanced 
expression of virus entry receptors could be observed due to HDACi 
treatment (Fig. 8). This mainly applies to coxsackie- and adenovirus 
receptor (CAR) which was found being frequently downregulated in 
several different tumor entities (Saito et al., 2014). The molecular 
mechanism, causing this phenomenon, was shown to be of 
epigenetic origin and thus, is in posse to be modified by treatment 
with HDACis (Sachs et al., 2004, Ma et al., 2012). There is further 
evidence that entry receptors of other viruses can be upregulated 
as well. A conjunction treatment of an equine HSV (EHV) and VPA 
in human glioblastoma cells resulted in an increased virus entry 
when VPA was given 24 hours before virus infection. In the same 
manner, an enhanced viral spread was observed. The authors 
suggest that these findings could be explained by MHC-I 
upregulation which can serve as an entry receptor for EHV, since it 
is capable of binding to the glycoprotein D (White and Frampton, 
2013). 
Considering the application in vivo, both agents have proven their 
positive impact on the immune system. Because of these findings, 
one might suggest that the combination is able to elicit even more 
remarkable effects. In order to prove this thesis, clinical studies 
have to be conducted but are still outstanding. However, in an 
integrated approach investigating a combination of a viral vaccine, 
an OV and a HDACi (entinostat), the secondary antitumor immune 
response was not further enhanced following HDACi application but 
fortunately, a lower production of neutralizing antibodies as well as 
decreased numbers of T cells, directed against the OV, were 
observed (Bridle et al., 2013). 
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1.6. Objectives 
Based on an auspicious preliminary study conducted by our 
research group, investigating a combination of oncolytic measles 
virus armed with a prodrug convertase (MeV-SCD) and the HDACi 
resminostat on different hepatoma cell lines (Ruf et al., 2015), the 
aim of this dissertation was to evaluate this specific epi-
virotherapeutic approach for the treatment of advanced pancreatic 
cancer and to gain further inside into a possible synergistic mode of 
action. Regarding synergistic working points found in our previous 
work, it was pointed out that resminostat hindered tumor cells to 
express ISG in hepatoma cell lines (Ruf et al., 2015). Furthermore, 
an induction of apoptosis was observed and even more strikingly, 
no impairment of virus replication and propagation could be 
revealed. 
Since pancreatic cancer is associated with a miserable prognosis 
and there is still a dramatic lack in efficient therapeutic options, it 
should be regarded as a tumor entity that is well suited for 
establishing new therapeutic agents. In respect thereof, our 
previous results from the treatment of HCC should be tested for a 
broader spectrum of efficiency, i.e. in pancreatic cancer as well. 
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2. Materials and Methods 
2.1. Safety of laboratory 
All experiments described below were performed in our laboratory 
at the Hertie-Institut, Tübingen, complying Biosafety Level 2 of the 
Directive 2000/54/EC, biological agents at work from the European 
Parliament from the year 2000. In order to accomplish these 
requirements, most of the work was executed under a laminar flow 
hood (HERAsafe). Before and after usage the work surface was 
cleaned with 70% Isopropanol (SAV Liquid Production; Flintsbach 
a. Inn, Germany) or Descosept (Dr. Schuhmacher GmbH; Melsun-
gen, Germany) in case of experiments involving oncolytic viruses, 
respectively. After use, all materials were additionally irradiated with 
UV-light to inactivate viral particles and then autoclaved. 
 
2.2. Pancreatic cancer cell culture 
Pancreatic cancer cell lines (AsPC-1, BxPC-3, MiaPaCa-2 and 
PanC-1) obtained from the European Collection of Authenticated 
Cell Cultures (ECACC) were cultured in cell culture flasks in 
Dulbecco’s modified Eagle’s Medium (DMEM) (SIGMA high 
glucose; 4.5 g/L; L-Glutamine) containing 10% fetal calf serum 
(FCS) (DMEM-10). To provide optimal living conditions, cells were 
kept under humid atmosphere in an incubator at 37°C containing 
5% CO2. Sterile working conditions were ensured by the work bench 
HERAsafe. 
 
2.2.1. Harvesting and splitting of cells 
Cell cultures were passaged about twice a week in order to avoid a 
lack of nutrients and a deceleration of cell division rate. 
Initially, the old medium had to be aspirated, afterwards cells were 
gently washed with pre-warmed (37°C) phosphate buffered saline 
(PBS). To detach cells from the flask bottom, EDTA-trypsin was 
added and cells were incubated at 37°C till they were disengaged 
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from the bottom (duration differed between different cell lines). Then 
fresh DMEM-10 was added to inactivate trypsin. 1/2 to 1/10 of the 
cell suspension was kept for further cultivation. Flasks were refilled 
with fresh medium and placed in the incubator again. 
  
2.2.2. Cryoconservation of cells 
To provide a continuous supply of fresh cells, five cryovials of 
pancreatic cancer cells from each cell line were frozen at -180°C. 
For this purpose, cells were trypsinized as described above and the 
cell suspension was centrifuged at 1200 rpm for five minutes at 
room temperature. The cell pellet was resuspended in DMEM 
containing 10% dimethylsulfoxide (DMSO) and 20% FCS. 1 ml 
aliquots were transferred into cryovials and frozen at -80 °C. The 
next day they were transferred to -180 °C. 
 
2.2.3. Thawing of cells  
When new cells had to be taken into culture, cryovials were 
removed from the freezer and thawed quickly at 37°C in the water 
bath. Then cells were diluted in fresh pre-warmed DMEM-10 and 
centrifuged at 1200 rpm for five minutes. The cell pellet was again 
resuspended in medium and transferred to culture flasks. 
 
2.2.4. Counting cells 
Comparable to counting blood cells by employing a microscope, an 
improved Neubauer haemocytometer was utilized for determining 
cancer cell concentrations. A Neubauer haemocytometer consists 
of engraved squares of different size. The large squares at the 
corners are usually used for white blood cells whereas the 
subdivided smaller squares in the middle are usually used for red 
blood cells and platelets. Because of similar size and 
concentrations of cancer and white blood cells, the four big edge-
squares, covering 1 mm2 were used to count cancer cells. 
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To exclude dead cells, one tenth of cell suspension was mingled 
with nine tenths of trypan blue. This aqueous solution was pipetted 
under the cover glass which had been placed over the counting 
chamber, leaving a space of 0.1 mm. Since one square covers 1 
mm2 and the distance between the chamber and the cover glass is 
0.1 mm, 0.1 µl solution fits into the space, implying that the amount 
of counted cells had to be multiplied by 104. Considering ancillarily 
the dilution factor of 10, the concentration of cells per ml is given by 
105 times the counted cells. 
 
2.3. Virological methods 
2.3.1. Virus infection of pancreatic cancer cells 
Pancreatic cancer cells were seeded in 6-well or 24-well plates the 
day before treatment (Tab. 1). Measles virus (MeV) was thawed and 
vigorously vortexed in order to equally distribute the viruses.  
Table 1: Summarization of the amount of pancreatic cancer cells per well on 6- and 
24- well plates 
Pancreatic cancer 
cell line 
6-well plates 24-well plates 
AsPC-1 4 X 105 4 X 104 
BxPC-3 4 X 105 4 X 104 
MIA PaCa-2 2 X 105 2 X 104 
PANC-1 2.5 X 105 3 X 104 
 
According to the required multiplicity of infection (MOI), the amount 
of applied virus was calculated and diluted in Opti-MEM (Gibco; 
Grand Island, NY). Old medium was removed from pancreatic 
cancer cells, cells were washed with PBS and subsequently 
infected by adding 250 µl of virus dilution. After the infection period 
of three hours, the inoculum was removed and fresh DMEM-10 was 
added (Fig. 9). In case of a combination experiment or a mono-
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treatment experiment with resminostat (4-SC, Planegg-Martinsried, 
Germany), the new DMEM medium contained the required 
concentration of resminostat. 
 
 
 
Figure 9:  Timeline of virus infection and treatment 
 
 
2.4. Determining cytotoxicity to pancreatic cancer cells 
2.4.1. SRB cell viability assays 
The sulforhodamine B (SRB) assay is a very well suited method to 
perform cytotoxicity screenings. Since the dye binds to basic amino-
acid residues of cellular proteins and each cell from one distinct cell 
line has an almost equal protein composition, it might be assumed 
that SRB absorption is proportional to the cell mass per well (Vichai 
and Kirtikara, 2006). 
For this reason SRB staining was chosen in order to investigate how 
many cells in relation to MOCK-treated cells survived virus-
mediated oncolysis and HDACi-induced cytotoxicity, respectively. 
Therefore, medium was removed after the required time period, 
wells were thoroughly washed with PBS, followed by cell fixation 
with 10% trichloroacetic acid (TCA). Afterwards, plates were stored 
for 30 minutes at 4°C and then washed with tap water for four times 
and stored at 40°C over night until they were entirely dry. 
The next day, fixed cells were covered for at least 10 minutes with 
250 µl SRB staining solution (0.4% w/v in 1% acetic acid) and 
afterwards washed with 1% acetic acid. After having been dried 
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again, one to two ml 10 mM TRIS base solution (pH 10.5) were 
added to the plates in order to solubilize SRB from cell proteins. 
Subsequently, 80 µl of the solution from one well were transferred 
in duplicates to a 96-well plate and the extinction was measured by 
using a microplate photometer (Tecan Genios Plus) at a wavelength 
of 550 nm. The results were expressed as percentage of MOCK-
treated cells. 
 
2.4.2. Real-time cell proliferation assay 
The real-time cell proliferation assay was performed with the 
xCELLigence system employed (Roche Applied Science, 
Mannheim, Germany) which is based on electronic impedance 
sensors integrated on a typical 96-well plate. Since cells adhere to 
the bottom of wells, the amount of cells and the extent of adhesion 
are responsible for the electrical impedance. Consequently, an 
increase in impedance results from a higher amount of cells or an 
increase in cell adhesion. Measurements were expressed in cell 
index (CI) value which was determined through the proportion to the 
initial value. Thus, changes in cell morphology, viability or adhesion 
induce changes in cell index value (ACEA Biosciences, 2013). 
In contrast to other experiments that comprised virus infection and 
resminostat treatment, no change of medium was performed. 
Hence, the treatment scheme differed from those of previous 
experiments (Fig. 10). 
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Figure 10: Exemplary pipetting scheme of the 96-well plate for xCELLigence 
 
At the beginning the background impedance had to be determined. 
Therefore, each well was filled with 50 µl DMEM-10 and put in the 
xCELLigence station at 37°C. Cells were seeded in concentrations 
with respect to their particular proliferation characteristics which 
were determined before (AsPC-1:10,000 cells per well; BxPC-3: 
2,500 cells per well; MIA PaCa-2: 7,500 cells per well; PANC-1: 
5,000 cells per well).  
Cells were added in 100 µl DMEM supplemented with only 2.5% 
FCS. 21 hours after cell seeding, MeV diluted in 10 µl Opti-MEM 
was pipetted to required wells, infecting at MOIs as commonly used 
(5 for AsPC-1, 0.5 for BxPC-3, 2.5 for MIA PaCa-2 and 0.25 for 
PANC-1). Wells that were only MOCK- or HDACi-treated, were 
equally filled with 10 µl Opti-MEM. Hence, each well contained now 
160 µl medium. After three more hours, 50 µl DMEM containing 
27% FCS and, if required, additionally resminostat (1 µM for AsPC-
1 and MIA PaCa-2, 2.5 µM for BxPC-3 and 5 µM for PANC-1), were 
added with the result that cell medium was finally supplemented 
with 10% FCS. 
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Figure 11: Timeline of combination treatment for xCELLigence experiments 
 
The array of cell lines and mode of treatment were arranged as 
shown in (Fig. 11).  
 
2.5. Virus growth curves in pancreatic cancer cells 
2.5.1. Obtaining virus samples 
The four pancreatic cancer cell lines were seeded one day before 
virus infection in 24-well plates in 500 µl DMEM-10 (Tab. 1 shows 
the amounts of cells per well for each pancreatic cancer cell line). 
Measles virus was added in Opti-MEM at MOIs of 0.25, 0.5, 2.5 and 
5 for PANC-1, BxPC-3, MIA PaCa-2 and AsPC-1, respectively. 
Cells were infected as described above. After three hours, Opti-
MEM was removed and cells were washed with PBS for three times. 
Afterwards, 500 µl DMEM-10 were added if required, containing 
supplementary resminostat in following concentrations: 1 µM for 
AsPC-1 and MIA PaCa-2, 2.5 µM for BxPC-3 and 5 µM for PANC-
1. In order to quantify virus replication over the post infection period, 
samples were taken at 3, 24, 48, 72 and 96 hours post infection 
(hpi). Therefore supernatants were transferred into 2 ml eppendorf-
tubes, 500 µl Opti-MEM were added to the remaining cells which 
were finally scraped off the bottom of wells by using a 1000 µl 
pipette. Cell suspensions were also transferred into 2 ml eppendorf-
tubes. Altogether, there were four samples for each time point, in 
each case two samples with supernatant and two with cell 
suspension. Both had been treated with measles virus but one of 
them had been additionally treated with resminostat. All samples 
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were stored at - 80°C in order to lyse cells and consequently release 
virus. 
 
2.5.2. Virus titration on Vero cells 
Virus growth kinetics were determined by infecting Vero cells 
obtained from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). In order to quantify 
viruses, dilution series of samples taken at different points in time, 
as described above, were prepared. For this purpose, samples 
were thawed, carefully vortexed and subsequently centrifuged for 
two minutes at 3000 rpm. 300 µl of each sample were pipetted into 
a 96-well dilution plate as shown in (Fig. 12).  
  
Figure 12: Pipetting scheme preparing titration 
 
All other wells were filled with 270 µl DMEM medium containing 5% 
FCS (DMEM-5). Finally, 30 µl from the first column were transferred 
to the next one and resuspended. This step was repeated till the 
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last column was reached. Consequently, each column contained 
one tenth of unknown virus concentration as compared to the one 
before. 
After having created this 1:10 dilution series, samples were added 
to the Vero cells which had been seeded in 96-well plates at a 
density of 104 cells per well in DMEM-5 the day before. Each row of 
the dilution was used to infect four rows of Vero cells. In order to 
determine the exact virus concentration, Vero cells were examined 
whether they were infected with MeV after 96 hours. Since MeV 
carried a gene encoding for green fluorescent protein (GFP), 
infected cells produced GFP and consequently, virus infection could 
be detected and quantified by using a fluorescence microscope. A 
“positive” well was defined as at least one green plaque, 
representing a Vero cell syncytium formed due to infection by 
replication-competent MeV. More precisely, exact concentrations 
were calculated from the Tissue Culture Infective Dose (TCID50) 
was as described by Spearman and Kärber (Karber, 1931, 
Spearman, 1908) (Fig. 13)  
 
TCID50 
1
ml
=
𝑁viral particles
1 ml
=  
101+(𝑁infected wells−0.5∙log(10))
0.03 ∙ 𝑉inserted viral solution
 
Figure 13: TCID50-formula by Spearman (1908) and Kärber (1931) 
  
The TCID50 is defined as the required amount of virus that is needed 
to produce a cytopathic effect in 50% of inoculated tissue culture 
cells. 
 
 
2.6. Verification of decrease in levels of zinc-finger protein 64  
2.6.1. Obtaining RNA samples 
Pancreatic cancer cells were seeded in 6-well plates and 24 hours 
later MOCK-treated, treated with resminostat or / and infected with 
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MeV-GFP, respectively, applying concentrations and MOIs 
according to (Tab. 1). After 5 and 24 hours, medium was removed; 
cells were washed with PBS (2 ml) and afterwards scraped off the 
bottom of wells in PBS. Subsequently, the cell solution was 
transferred to a 2- ml Eppendorf-Cup and centrifugated at 5000 rpm 
for five minutes. In order to isolate RNA from the cell suspension, 
the NucleoSpin® RNA kit (Macherey-Nagel, Düren, Germany) was 
employed following the manufacturer´s instructions. 
 
2.6.2. qPCR of zfp 64 mRNA 
“RT buffer (Promega, Madison, WI, USA), 1 μl RNase- RNasin Plus 
(Promega), 1 μl oligo-dT-Primer (0.5 μg/μl) (TIB MolBio, Berlin, 
Germany), 0.5 μl dNTP mix (Roti-Mix PCR3, Carl Roth) and added 
up to a total volume of 9.6 μl in RNAse-free water. Samples were 
then incubated at 70˚C for 2 min. After adding 0.4 μl reverse-
transcriptase M-MLV RT H(-) Point Mutant (Promega), samples 
were incubated at 42˚C for 60 min. 
The cDNA samples diluted (1/40) with tRNA-H2O; primers were 
used in a concentration of 500 nM. PCR was carried out in an 
iCycler (Bio-Rad) with iQ5 Multicolor Real‑time Detection system 
(Bio-Rad), using the following setup: 10 μl iQSYBR Green PCR 
Master Mix (Promega), 0.1 μl of each primer (100 μM stock), 5.8 μl 
H2O and 4 μl cDNA (diluted 1/40). The following primer pairs were 
used: zfp64 (splicing variants 1,3,4) forward, ACCTGCCCACGGAA 
AGTAAT; zfp64 (splicing variants 1,3,4) reverse, TATGGGG 
TTTGTCTCCCGTG; RPS18 (housekeeping gene) forward, 
GAGGATGAGGTGGAACGTGT; RPS18 reverse, TCTTCAG 
TCGCTCCAGGTCT. PCR was carried out with the following 
thermal profile: 3 min at 95˚C with subsequently 40 cycles for 15 
sec at 95˚C, 20 sec at 58˚C, and 15 sec at 62˚C. Heating up for 1 
min at 95˚C was followed by 1 min at 65˚C and 81 cycles at 65˚C 
cooling down to 20˚C. Target gene expression was evaluated via 
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the 2-ΔCt method and normalized to the housekeeping gene 
RPS18 and subsequently graphed relative to the respective mock 
sample for each time-point and expressed as ‘relative gene 
expression’.” (Ellerhoff et al., 2016)  
 
2.7. Detection of IFN-stimulated genes proteins by immunoblotting 
2.7.1. Preparation of cell lysates 
Pancreatic cancer cells were seeded in 6-well plates (for amounts 
per well see Tab. 1) and infected with MeV-GFP in presence or 
absence of resminostat. Furthermore, few cells were stimulated 
with IFN-β after three hours. After different time periods cells were 
harvested. For this purpose, medium was removed, cells were 
washed with PBS and scraped off the wells´ bottom in PBS. Cell 
suspensions were centrifuged at 4000 rpm for five minutes. Cell 
pellets were resuspended in lysis buffer (50 mM Tris pH 7.6, 150 
mM NaCl, 1% IGEPAL Sigma Aldrich) whereby the required amount 
depended on the size of the pellet. Cell lysis was performed by three 
freeze-thaw cycles. Therefore, cell samples were defrosted at 37°C 
in the water bath and subsequently shock frozen in liquid nitrogen. 
Finally cells were spun down for ten minutes at 13000 rpm at 4°C 
and supernatants containing released cellular proteins were 
transferred to Eppendorf-tubes and stored at - 20°C. 
 
2.7.2. Determination of protein concentration following the Bradford- 
method 
After cell lysis, protein concentrations were determined applying the 
Bradford method (Bradford, 1976). Therefore, cell lysates were 
diluted 1:40 with double-distilled water (ddH2O). According to figure 
14, a series of standard dilutions of bovine serum albumin (BSA) 
covering protein concentrations from 0.5 to 0.05 mg/ml were 
pipetted in the first two rows of a 96-well plate. To determine the 
blank value, ddH2O was added to the dilution row. The remaining 
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samples were transferred in duplicates to two wells. All wells were 
filled with 10 µl solution (BSA and cell lysate, respectively) (Fig. 14). 
 
 
Figure 14: Pipetting scheme for Bradford protein determination 
 
Afterwards, the Bradford reagent (BIO-Rad) was diluted 1:5 with 
water and 200 µl of this dilution were subsequently transferred to 
each well. Its component Coomassie Brilliant Blue G-250 dye forms 
complexes with proteins which shift the absorption maximum from 
465 nm to 595 nm. This implies that the higher the concentration of 
proteins in solution, the greater is the extent of absorption at 595 
nm. Therefore, the extinction was measured at 595 nm utilizing the 
ELISA reader. The precise amount of protein in each sample was 
calculated on basis of the standard curve of BSA. 
 
 
 
2.7.3. SDS-Page 
For the purpose of separating proteins according to their size, a 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
Page) was performed. This method was initially implemented by 
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Laemmli (Laemmli, 1970) and takes advantage of the ability of SDS 
to overlap charges of proteins by disrupting non-covalent bonds. 
Consequently, polypeptide chains are unfolded and proteins are 
charged negative. Therefore, they can be separated by size, without 
considering their charge.  
Two gels were prepared applying the formulas shown in (Tab. 2 ). 
To bring the gels into shape, two plane parallel glass plates were 
assembled in a distance of 1.5 mm. Initially, the resolving gel was 
funneled into the created chamber and then, isopropanol was 
added to create a flat surface. Since tetramethylethylenediamine 
(TEMED) serves as a catalyst and ammonium persulfate (APS) as 
a radical initiator, polymerization starts subsequently after 
admixture of these two ingredients and took at least 15 minutes. 
After having discarded isopropanol and washed the gels´ surface 
with water, the stacking gel was filled over the resolving gel and a 
comb was inserted to form pockets for protein samples.  
  
Materials and Methods 
 
- 46 - 
 
Table 2: Ingredients of gels used for electrophoresis 
8 % resolving gel (for two 
gels) 
5 % stacking gel (for two 
gels) 
 
- 9.3 ml ddH2O 
- 5.0 ml 1.5 M Tris-HCl pH = 8.8 
- 5.3 ml Acrylamide mix 30% 
- 200 µl 10% SDS 
- 200 µl 10% Ammonium 
persulphate (APS) 
- 12 µl TEMED 
 
- 4.1 ml ddH2O 
- 1.0 ml 1.0 M Tris-HCl pH = 6.8 
- 750 µl Acrylamid mix 30% 
- 60 µl 10% SDS 
- 60 µl 10% Ammonium 
persulphate (APS) 
- 6 µl TEMED 
 
vAfter both gels had polymerized, they were put into an 
electrophoresis chamber which was filled with running buffer (5X 
buffer: 15.1 g Tris, 72 g glycine, 5 g SDS in 1 l of ddH2O). 
70 µg of each protein sample were enriched with one sixth loading 
buffer (β-mercaptoethanol) and denaturated in a heating block for 
five minutes at 95°C. Both steps are essential for breaking down 
secondary and tertiary structures of proteins, enabling to bring the 
proteins into the gel pockets. Furthermore, a positive control (IFN-
treated) and a molecular weight marker (PageRuler Plus protein 
ladder (Thermo Scientific, Waltham, MA)) were added to each row 
of protein samples. The fractionation of proteins was performed by 
applying a voltage of 70 V and a current of 40 mA, respectively.  
 
2.7.4. Western Blot 
With the objective of detecting specific proteins, separated proteins 
from the cell lysates were transferred from the gel to a 
polyvinylidene difluoride- (PVDF) membrane (Amersham Hybond 
P, GE Healthcare). For this purpose, the PVDF membrane and the 
gels were fastened in spatial proximity by using clamps (sandwich) 
and were finally put in transfer buffer (Tris 48 mM, Glycine 39 mM, 
MeOH 20%) applying a current of 300 mA for one hour. After having 
performed the transfer, membranes were washed with methanol 
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and stained with Ponceau S red dye solution (Roth; 0.1% (w/v)) to 
check whether the proteins were actually and accurately transferred 
to the membranes without air bubbles. Membranes were 
subsequently blocked for one hour with TBS-T (NaCl 150 mM, Tris 
50 mM, adjusted pH (7.4) with HCl, 0.02% Tween) supplemented 
with 5% milk powder, thereby preventing non-specific binding of 
antibodies used later. Overnight , membranes were incubated with 
primary antibodies (anti-IFIT1: GTX103452; 1:1000; GeneTex, 
Irvine, CA; anti-Phospho-Stat1: 58D61; 1:1000; Cell Signaling 
Technology, Danvers, MA; anti-Stat1: sc-591; 1:500; Santa Cruz 
Biotechnology, Santa Cruz, CA; anti-β-Actin: A 4700; 1:6000; 
Sigma Aldrich) continually pivoted on a shaker at 4°C. The next day, 
antibodies were removed and membranes were washed with TBS-
T three times for ten minutes. Afterwards, membranes were 
exposed to the secondary antibody (goat anti-rabbit IgG; goat anti-
mouse IgG; HRP-coupled; Abcam Ltd., Cambridgeshire, UK) 
dissolved in 5% milk powder in TBS-T for at least one hour. Then, 
membranes were washed again three times with TBS-T for ten 
minutes. 
To detect the sought proteins, ECL Western Blotting Detection 
Reagent (mixed 1:1, GE Healthcare) and photosensitive films (GE 
Healthcare) were utilized. Therefore, both components of the 
chemiluminescence kit were mixed in equal amounts and incubated 
with the membranes for one minute. Afterwards, membranes were 
covered by plastic sheets and put into photo cassettes (Dr. GOOS 
Suprema GmbH). Subsequently, films were developed in a dark 
room. The exposition times varied between different antibodies and 
protein samples. 
After protein bands had been detected, antibodies were stripped off 
membranes. Therefore PVDF membranes were incubated in 10 
mM NaOH for ten minutes and afterwards washed with TBS-T for 
three times. 
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Membranes were then reprobed with different antibodies in order to 
detect further proteins (in this case β-actin and STAT-1). 
 
2.8. Statistical analysis 
“The influence of measles and resminostat on the decadic logarithm 
of cell mass (in % of the mean of the cell line control) was examined 
by performing a two-way analysis of variance (ANOVA). 
Additionally, an interaction of measles and resminostat was used in 
the ANOVA. Calculations were done by the JMP software for 
windows. P-values <0.01 were considered to be statistically 
significant. Graphs including error bars were imaged with GraphPad 
Prism 4 for windows. “ (Ellerhoff et al., 2016) 
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3. Results 
Aiming to improve the classical virotherapy, an epi-virotherapeutic 
approach combining oncolytic measles virus (MeV-GFP) and the 
HDACi resminostat on four aggressive pancreatic cancer cell lines 
was investigated in the following experiments. 
At first, pancreatic cancer cell lines were evaluated for their 
sensitivity towards each agent in monotreatment. In these 
experiments the concentrations and MOIs were determined that 
were employed in combined epi-virotherapeutic experiments. 
Therefore, suitable dosages were defined leading to a remaining 
cell mass of 70-80% 96 hpi. After having found required 
concentrations, combination SRB cell viability assays were 
performed. The xCELLigence system was afterwards employed in 
order to confirm and further obtain more precise data regarding 
cooperative effects over the entire treatment period. 
To further elucidate underlying synergistic mechanisms, it was 
examined whether virus growth kinetics could be altered by 
concomitant treatment with resminostat. Then, it was investigated 
whether resminostat´s pharmacodynamic function is potentially 
impaired in MeV-GFP-infected pancreatic cancer cells. Finally, 
resminostat-related modulation of MeV-GFP-induced activation of 
interferon(IFN)-signaling as a potential therapeutic target was 
analyzed. 
 
3.1. Analysis of cytoreductive effects induced by oncolytic measles 
virus and resminostat on pancreatic cancer cells 
3.1.1. Resminostat-induced cytotoxic effects  
To get an overview of the time and dose-dependent effects of 
resminostat on pancreatic cancer cells, SRB cell viability assays 
were performed, examining cytoreductive effects of six ascending 
concentrations of resminostat (MOCK, 0.5, 1, 2.5, 5, 10 µM) at four 
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consecutive time points (24, 48, 72 and 96 hours post treatment 
(hpt)). 
After having seeded cancer cells the day before, medium was 
removed and resminostat diluted within 500 µl medium (DMEM plus 
10% FCS) was added. The remaining cell mass was quantified by 
SRB viability assays at 24, 48, 72 and 96 hpt.  
Treatment with resminostat resulted in a dose- and time-dependent 
reduction of cell mass in all four tested pancreatic cancer cell lines. 
With the exception of MIA PaCa-2, all other cell lines did not exhibit 
a reduction in cell mass 24 hpt (Fig. 15). The other three cell lines 
featured a reduction in cell mass not until 48 hpt, indicating that 
resminostat-related cell death typically is induced between 24 and 
48 hpt.  
Whereas cell viability of BxPC-3 and MIA PaCa-2 cells (Fig. 15) did 
not further decrease between 72 and 96 hpt, a decrease in cell 
masses of AsPC-1 as well as PANC-1 was still observed. This 
implies that the period of cytoreductive effects of resminostat seems 
to vary between cell lines, irrespective of concentrations.  
 
„ 
 
Figure 15: Evaluation of resminostat-induced pancreatic cancer cell mass reduction 
Monotreatment with the epigenetic compound resminostat resulted in a dose- and time-
dependent reduction of tumor cell masses in all tested pancreatic cancer cell lines (AsPC-
1, BxPC-3, MIA PaCa-2 and PANC‑1). Six concentrations of resminostat (ranging from 0 
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to 10 μM) were administered and tumor cell viabilities were determined at four different 
time-points (24, 48, 72 and 96 h after treatment) utilizing a Sulforhodamine B (SRB) 
viability assay. Tumor cell masses are given in % of the mean of mock-treated tumor cells 
(resminostat concentration of 0 μM) for each time-point. Means and SDs of three 
independent experiments are shown.” (Ellerhoff et al., 2016) 
 
MIA PaCa-2 was the cell line that exhibited the earliest detectable 
reduction in cell mass and was also the most sensitive cell line. The 
conspicuous skip of cell mass between 1 µM and 2.5 µM 
resminostat is unique, as there is no similar feature in the results of 
other cell lines. In particular, resminostat concentrations of 0.5 and 
1 µM led to a reduction in cell mass up to 10 %, whereas 2.5 µM of 
resminostat even elicited a reduction of about 70 %. Treatment with 
the next higher concentration of 5 µM almost killed all seeded cells 
at 96 hpt.  
By contrast, PANC-1 cells were shown being most resistant towards 
resminostat. 70% of its cell mass remained at 96 hpt despite being 
exposed to the relatively high concentration of 5 µM of resminostat 
(Fig. 15).  
Taking the two other cell lines into account, BxPC-3 cells were more 
resistant than AsPC-1 cells. Comparing cell viability at a 
concentration of 2.5 µM, remaining cell masses of 65% of BxPC-3 
and 40% of AsPC-1 were obtained at 96 hpt. 
 
3.1.2. MeV-induced cytotoxic effects  
After having quantified the cytotoxic potency of resminostat, MeV-
GFP was examined for its time- and dose-dependent cytoreductive 
effects on pancreatic cancer cells by applying a series of ascending 
MOIs. 
Following the infection scheme described above, cell mass was 
determined at 72 and 96 hpi. In contrast to the SRB experiments 
with resminostat, both earlier time points 24 and 48 hpi were not 
examined this time. The rationale behind this procedure is based on 
the fact that previous experiments from our laboratory have already 
revealed that MeV-mediated oncolysis takes more time as 
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compared to classical cytotoxic drugs, since viruses have to initially 
occupy the synthetic machinery of host cells and cancer cells die 
only after several rounds of viral replication due to the induction of 
immunogenic cell death or self-induced apoptosis, respectively.  
Cell lines were infected at different MOIs, depending on their 
susceptibility toward virus-mediated oncolysis. Consequently, MeV-
GFP was characterized by a broader spectrum of efficiency than 
resminostat with respect to the distinct treated tumor type. After 
having infected cells at a MOI of 1.0, there were 50% of PANC-1 
cells as compared to the MOCK-treated control, whereas there 
were 75% of BxPC-3 cells and more notable, cells from both other 
cell lines remained unaffected at 96 hpi (Fig. 16 B and D).  
 
 
Figure 16: Evaluation of MeV‑GFP-induced pancreatic cancer cell mass reduction 
Mono-treatment with recombined measles virotherapeutics (MeV‑GFP) resulted in a 
dose- and time-dependent reduction of tumor cell masses in all pancreatic cancer cell lines 
(AsPC-1, BxPC-3, MIA PaCa-2 and PANC‑1). Virotherapeutic treatments were performed 
at indicated multiplicities of infection (50), being adjusted to the oncolytic susceptibility of 
the respective tumor cell line. Tumor cell viabilities were determined at 72 and 96 h post-
infection (hpi) using SRB viability assays. Tumor cell masses are given in % of the mean 
of mock-treated tumor cells for each time-point. Means and SDs of three independent 
experiments are shown. 
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Nonetheless, as shown for resminostat treatment, the extent of 
MeV-GFP-mediated oncolysis was shown to be dose- and time-
dependent.  
“The tumor cell line being most sensitive to MeV‑GFP-mediated 
oncolysis was PANC‑1 (Fig. 16 D), whereas AsPC-1 tumor cells 
(Fig. 16 A) were found to be most resistant. Considering this, more 
than 50% of AsPC-1 cells survived virus infections at a MOI of as 
high as 20. In contrast, a tumor cell mass reduction of 50% was 
obtained by infecting PANC‑1 cells at a MOI of as low as 1.” 
(Ellerhoff et al., 2016) 
As was already shown in several previous studies, MeV-GFP-
induced oncolysis was initiated at later time points as compared to 
the cytoreductive effects of resminostat. In the case of PANC-1 
cells, a measurable effect in comparison to the MOCK-treated 
control cells could not be detected until 96 hours. Cells of the other 
three cell lines exhibited a reduction in cell mass at 72 hpi which 
decreased further until 96 hpi. One explanation for the decrease in 
cell mass starting only at 96 hours after MeV-GFP infection may be 
deduced from the lowest MOIs, being applicated to PANC-1. 
Nonetheless, no decrease in cell viability could be detected 72 hpi 
after having been infected at a MOI of 1 whereas cell mass was 
remarkably reduced by over 50% during the following 24 hours. 
“Addressing the question whether there is cross-resistance 
between resminostat and MeV‑GFP, a remarkable trend could be 
observed. Tumor cell lines, which had been identified to be more 
resistant toward resminostat exhibited a relatively strong sensitivity 
toward MeV‑GFP-mediated oncolysis and vice versa. The largest 
difference in tumor cell susceptibility was obtained in experiments 
with the PANC‑1 tumor cell line being most resistant against 
resminostat treatment, but most sensitive towards MeV‑GFP-
mediated oncolysis (Figs. 2D and 3D).” (Ellerhoff et al., 2016) 
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3.1.3. Comparison between cytoreductive effects of MeV-GFP- or 
resminostat-monotreatment and epi-virotherapeutical treatment  
“To further determine whether resminostat and oncolytic MeV 
operate beneficially when administered in combination, pancreatic 
cancer cells were initially infected with MeV‑GFP; then, resminostat 
was added following the regular change of infection culture medium 
at 3 hpi (Fig. 17). Tumor cell line adjusted MOIs of MeV‑GFP and 
concentrations of resminostat were used as determined prior in the 
monotherapy settings.”(Ellerhoff et al., 2016) 
 
“
 
Figure 17: Epi-virotherapeutic treatment is superior to any corresponding 
monotherapy 
Tumor cells were infected with MeV‑GFP (MeV) at indicated multiplicities of infection (50), 
being adjusted to the oncolytic susceptibility of the respective tumor cell lines. At 3 h post 
infection (hpi), resminostat was added at the indicated concentrations. Remaining tumor 
cell masses were determined at 96 hpi using SRB viability assays. Means and SDs of 
three different experiments are shown. *P-value <0.01 of ANOVA on logarithms of tumor 
cell mass in % of control, comparing epi-virotherapeutic treatment with monotreatment of 
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resminostat (Res) and MeV. **P-value <0.01 of interaction term in ANOVA verifying a more 
than additive (synergistic) effect.” (Ellerhoff et al., 2016) 
  
“As a result, supplementation of oncolytic MeV‑GFP by resminostat 
resulted in beneficial effects on rates of tumor cell mass reduction 
in all tested pancreatic cancer cell lines. With regard to MOIs of MeV
‑GFP and concentrations of resminostat employed in later 
experiments, the reduction in tumor cell mass could be amplified 
from 53 to 37% for AsPC-1 (MOI 5), from 60 to 32% for BxPC-3 
(MOI 0.5), from 65 to 19% for MIA PaCa-2 (MOI 2.5), and from 93 
to 48% for PANC‑1 (MOI 0.25) (Fig. 17). Considering that HDACi 
per se induce a reduction in pancreatic cancer cell masses, the 
most striking benefit could be obtained in the treatment of MIA 
PaCa-2 cells, achieving a further 45% reduction in tumor cell mass 
(Fig. 17 C, comparison of bars 2 and 6). Whereas both agents in 
monotherapy reduced tumor cell viability each by 35% in 
comparison to the mock control, the combination led to a tumor cell 
mass reduction of >80% in comparison to the mock control (Fig. 17 
C, comparison of bars 1 and 6). A statistical analysis was carried 
out to investigate whether an interaction between MeV-GFP and 
resminostat is verifiable that caused a more pronounced effect on 
tumor cell mass reduction than expected from a simple additive 
effect. The interaction term in the ANOVA on the logarithms of 
tumor cell mass in % of control confirmed a clear significant 
synergistic antitumor effect for the treatment of MIA PaCa-2 cells 
(Fig. 17 C) as compared to the cytotoxic effect that would be 
expected from an additive effect. With regard to the other pancreatic 
cancer cell lines, synergistic tumor cell killing could be significantly 
revealed in PANC‑1 cells for only one of the two combinations (MeV 
MOI 0.375 and 5 μM resminostat; Fig. 17 D); in contrast, no 
synergistic effects were found for AsPC-1 and BxPC-3 tumor cells 
(Fig. 17 A and B), suggesting that the epi-virotherapeutic approach 
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does not elicit synergistic effects in all pancreatic cancer cell 
entities, presumably as a result of tumor cell specific features.” 
(Ellerhoff et al., 2016) 
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„
 
Figure 18: Detailed analysis of pancreatic cancer cell viability over 120 h of epi-virotherapeutic 
treatment. 
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Beneficial effects of epi-virotherapeutic co‑treatment were confirmed and specified by 
real-time proliferation monitoring providing tumor cell viability data over the entire 
treatment period of 120 h. Following the initial tumor cell seeding (at hour 0), three of the 
four pancreatic cancer cells (AsPC-1, MIA PaCa-2 and PANC‑1) were infected 21 h later 
with recombined measles virotherapeutics (MeV‑GFP) at MOIs used in SRB combination-
experiments or not treated (mock); then, at three hours post-infection, tumor cells were 
treated with the epitherapeutic compound resminostat (Res) at indicated concentrations. 
Treatment with Triton X-100 1%, inducing maximum tumor cell lysis, was used as a 
negative control. Cellular impedance was measured continuously using the xCELLigence 
SP system. Depicted are the data obtained in 6-h intervals. Cell index was normalized 
after 24 h when treatment had been accomplished (additional administration of 
resminostat or Triton X-100). Means and SDs of three different independent experiments 
are shown.” (Ellerhoff et al., 2016) 
 
“To confirm our results from the SRB viability assays and to gain 
more precise information on the entire treatment time course, real-
time pancreatic cancer cell proliferation was determined using the 
xCELLigence system (Fig. 18). The acquired data revealed that our 
epi-virotherapeutic treatment elicited beneficial effects on tumor cell 
viabilities in three out of the four tested pancreatic cancer cell lines 
(Fig. 18). Taken together, these findings underline that: i) our 
specific epi-virotherapeutic treatment is much more valuable for 
MIA PaCa-2 and PANC‑1 tumor cells than for AsPC-1 cells (BxPC-
3 tumor cells were not included in this specific testing) and ii) the 
mode of synergistic tumor cell killing is first observed at 72 hpi in all 
tested pancreatic cancer cell lines (going along with MeV-mediated 
oncolysis phenomena taking place at this time-point).” (Ellerhoff et 
al., 2016) 
In conclusion, epi-virotherapeutical treatment could elicit boosted 
anti-tumor effects in all pancreatic cancer cell lines. However, the 
extent differed from cell line to cell line, confirming solely a 
statistically significant synergistic interaction at both examined time 
points for MIA PaCa-2 cells. The presented results raise the 
questions whether there might be underlying molecular 
mechanisms explaining the synergistic mode of action or whether 
both agents work independently from each other. For this reason, 
virus growth kinetics were investigated in a further step with the aim 
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of assessing whether MeV-GFP replication and spread is possibly 
amplified by co-treatment with resminostat. 
 
 
3.2. Impact of epi-virotherapeutical treatment on measles growth 
kinetics in pancreatic cancer cells 
“To further determine whether resminostat and oncolytic MeV 
operate beneficially when administered in combination, pancreatic 
cancer cells were initially infected with MeV‑GFP; then, resminostat 
was added following the regular change of infection culture medium 
at 3 hpi. Tumor cell line adjusted MOIs of MeV‑GFP and 
concentrations of resminostat were used as determined prior in the 
monotherapy settings.” (Ellerhoff et al., 2016) 
 
3.2.1. Analysis of MeV-GFP growth kinetics in pancreatic cancer cells 
At first, virus growth characteristics were investigated in the four 
pancreatic cancer cell lines without co-treatment with resminostat 
(Fig. 19).  
 
 
Figure 19: Virus growth curves of pancreatic cancer cells infected with MeV-GFP 
Tumor cells were infected at different MOIs. AsPC-1 at 5, BxPC-3 at 0.5, MIA PaCa-2 at 
2.5 and PANC-1 at 0.25. Samples were taken at 3, 24, 48, 72 and 96 h post-infection (hpi). 
Tumor cell lysates (curves to the left, solid lines) provide information on viral particles being 
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found in intact tumor cells, whereas supernatant samples (curves to the right, dotted lines) 
reflect the release of newly generated infectious MeV‑GFP particles from tumor cells. 
Results were obtained by virus titration on Vero cells. Displayed are means and SDs of 
three independent experiments. pfu, plaque forming unit; hpi, hours post-infection.” 
 
Similar features could be identified in all tested pancreatic cancer 
cell lines. The amount of virus both released and cell-associated did 
not start increasing until 24 hpi and reached a plateau at around 72 
hpi or even started decreasing three days post infection in case of 
BxPC-3 cells. The highest virus titers were reached in PANC-1 and 
MIA PaCa-2 cells (Fig. 20 C and D), amounting 105 PFU/ml 
whereas in AsPC-1 and BxPC-3 only 104 PFU/ml were detected 
(Fig. 19 A and B).  
Comparing the viral titers in supernatants and in cell lysates, viral 
concentrations in cells were almost equal to those in medium. This 
was found in all four pancreatic cancer cell lines.  
With regard to the quantity of virus titers, it might be expected that 
cell lines infected at higher MOIs should produce higher titers in 
comparison to cell lines infected at lower MOIs. AsPC-1 cells that 
were infected at the highest MOI (5), did not yield the highest viral 
titer (Fig. 19 A). Nonetheless, primary viral titers (3 hpi both in cell 
lysates and supernatants) were the highest among all four 
pancreatic cancer cells as might be deduced from the highest MOI. 
AsPC-1 and BxPC-3 cells were seeded at higher densities 
compared to the other two cell lines but did not reach the highest 
virus titers (Fig. 19 A and B). Likewise, no clear correlation between 
the sensitivity towards MeV-GFP-mediated oncolysis and the 
amount of detected viruses could be observed. As a proof, BxPC-3 
cells were shown to be more sensitive than MIA PaCa-2 cells but 
yielded lower MeV-GFP virus titers (Fig. 19 B and C).  
SRB assays had revealed that MeV-mediated oncolysis did not 
occur until 72 hpi, suggesting that virus release should emerge 
around this time point. In contrast to this consideration, great 
amounts of MeV-GFP were already released 48 hpi, indicating that 
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MeV first occupies the synthetic machinery and subsequently forces 
host cells to produce viral progenies. Finally, after having created a 
great amount of progenies, the synthetic machinery of host cancer 
cells collapses and consequently cells are compelled to initiate 
apoptosis.  
 
3.2.2. Comparison of MeV-GFP growth kinetics in presence and absence 
of resminostat in pancreatic cancer cells 
„ 
Virus growth curves of well characterized pancreatic cancer cell lines did not exhibit 
significant differences of measles virotherapeutic replication when being determined in 
absence or in presence of the epigenetic compound resminostat. Tumor cells were co-
treated with MeV‑GFP (MeV) and resminostat (Res) at stated multiplicities of infection 
(MOIs) and concentrations of the epigenetic compound (μM). Samples were taken at 3, 
24, 48, 72 and 96 h post-infection (hpi). Tumor cell lysates (curves to the left, solid lines) 
provide information on viral particles being found in intact tumor cells, whereas 
Figure 20: Resminostat co-treatment did not alter MeV‑GFP growth kinetics 
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supernatant samples (curves to the right, dotted lines) reflect the release of newly 
generated infectious MeV‑GFP particles from tumor cells. Results were obtained by virus 
titration on Vero cells. Displayed are means and SDs of three independent experiments. 
pfu, plaque forming unit; hpi, hours post-infection.” (Ellerhoff et al., 2016) 
 
Next, MeV-GFP growth kinetics were determined in presence of 
resminostat and compared to those obtained by monotreatment 
with MeV-GFP. In respect of the curve shapes of epi-viro-
therapeutical treatment, no significant differences were obtained 
when compared to those growth curves obtained by MeV-GFP-
infected pancreatic cancer cells (Fig. 20).  
“At later time-points (at 72 and 96 hpi) viral titers were slightly lower 
in supernatants as well as in tumor cell lysates in the presence of 
resminostat. This may be due to a greater tumor cell mass reduction 
induced by the combination treatment at later time-points, so that 
fewer tumor cells were present in the cultures at these later time-
points resulting in a significantly lower cellular capacity for 
production of viral progeny particles. In conclusion, enhanced 
oncolytic effects by the combined treatment of MeV‑GFP and 
resminostat were not found to be caused by an enhancement of 
viral replication by the HDACi.” (Ellerhoff et al., 2016) 
 
 
3.3. Analysis of pharmacodynamic function of resminostat in MeV 
infected pancreatic cancer cells 
“Decrease in the expression of zinc finger protein 64 (zfp64) has 
been revealed to be a good surrogate parameter for the 
pharmacological activity of resminostat. Therefore, we examined 
mRNA expression of zfp64 after monotreatment with either 
resminostat or MeV‑GFP and after combination treatment 
(resminostat plus MeV‑GFP) using the same resminostat 
concentrations and MOIs as in all prior experiments (Fig. 21). In the 
presence of resminostat, zfp64 expression was found to be 
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downregulated in each tumor cell line as early as after five hours of 
treatment initiation. Under epi-virotherapeutic co-treatment with 
resminostat and MeV‑GFP, we still observed a lower expression of 
zfp64 as compared to the mock-treated control (with AsPC-1 tumor 
cells showing an even lower expression under co-treatment as 
compared to resminostat treatment alone; Fig. 21 A).  
 
„
 
Figure 21: Analysis of the resminostat pharmacodynamic function in MeV‑GFP-
infected pancreatic cancer cells 
Unimpairment of the resminostat (Res) pharmacodynamic function in pancreatic cancer 
cells being infected with recombined measles virotherapeutics (MeV‑GFP) was deduced 
from the decrease in expression of zinc-finger protein 64 (zfp64) after 5 h of epigenetic 
treatment. Tumor cells were infected with MeV‑GFP at stated MOIs and co-treated with 
indicated concentrations of resminostat starting at 3 h post-infection. RNA samples were 
obtained after 5 h of treatment. Expression levels of zfp64, representing a well-defined 
surrogate parameter for the epigenetic impact of resminostat, were determined using RT-
qPCR. Values were normalized to the housekeeping gene RPS 18 (ribosomal protein 
S18), and relative expression is displayed compared to corresponding control samples 
(mock; no infection with MeV‑GFP and no treatment with resminostat). Data of a 
representative experiment are shown. MeV + Res, co treatment with measles virus MeV‑
GFP and resminostat with concentrations and MOIs as used in the respective mono-
treatment experiments.” (Ellerhoff et al., 2016)  
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In contrast, different expression patterns of zfp64 were found when 
tumor cells had only been infected with MeV‑GFP; in these cases, 
zfp64 was only downregulated in BxPC-3 and MIA PaCa-2 tumor 
cells (Fig. 21 B and C), but there was no detectable regulation in 
AsPC-1 and PANC‑1 tumor cells (Fig. 21 A and D). In conclusion, 
our experiments provide evidence that the pharmacodynamic 
function of resminostat did not seem to be impaired in MeV‑GFP-
infected pancreatic cancer cell lines.” (Ellerhoff et al., 2016) 
 
 
3.4. Impact of resminostat on MeV-GFP-activated JAK/STAT signaling in 
pancreatic cancer cells 
“In most studies investigating epi-virotherapeutic approaches so far, 
damping of the anti-viral response by HDACi was highlighted as a 
potential explanation for underlying synergistic antitumoral effects 
of this combined treatment approach. Accordingly, we were 
interested in the functionality of IFN‑signaling of pancreatic cancer 
cells in the presence and absence of resminostat during infections 
with MeV‑GFP.” (Ellerhoff et al., 2016) 
For this reason, phosphorylation of STAT1 and expression of the 
IFN-stimulated-gene (ISG) IFIT1 were investigated by immuno-
blotting. STAT1 gets phosphorylated after binding of IFN to its 
receptor causing hetero- and homodimerisation, thereby forming a 
complex with STAT2 and IRF9 which subsequently enters the 
nucleus with the objective of initiating transcription of ISGs 
(Schneider et al., 2014). One of the emerging ISGs is IFIT1, being 
assigned for detection of viral RNA as well as binding and 
inactivating of viral pathogenic proteins (Diamond and Farzan, 
2013). To ensure that proteins were loaded in equal amounts, 
membranes were additionally incubated with antibodies against 
STAT and β-actin. 
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3.4.1. Analysis of JAK/STAT-signaling after MeV-GFP infection  
Since approximately 80% of cancer cells have lost their ability of 
producing a proper IFN-mediated antiviral response (Stojdl et al., 
2003), it was first investigated whether pancreatic cancer cells have 
the ability of activating IFN signaling due to MeV-GFP infection.  
As a phosphorylation of STAT1 and an expression of IFIT1 were 
observed in AsPC-1, BxPC-3 and PANC-1 cells at 72 hpi it is in all 
probability suggested that activation of IFN signaling functioned 
appropriately in these cell lines. In contrast, neither phosphorylation 
of STAT1 nor expression of IFIT1 were detectable in MIA PaCa-2 
cells (Fig. 22), being indicative of defects in the IFN-signaling 
pathway of those cells. 
 
 
Figure 22: MeV‑GFP did not induce IFN signaling in MIA PaCa-2 cells 
Tumor cells were either infected with MeV‑GFP (MOI 2.5) or treated without infection 
(mock); then, samples were taken at 24, 48, 72 and 96 hours post-infection (hpi) and 
analyzed by immunoblotting; tumor cells stimulated with interferon-β (IFN‑β) were used 
as positive controls. Potential activation of IFN signaling by MeV‑GFP was deduced from 
phosphorylation of STAT1 (phospho-STAT1) and expression of interferon-induced protein 
with tetratricopeptide repeats 1 (IFIT1). β-actin was used as a loading control.” (Ellerhoff 
et al., 2016) 
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3.4.2. Analysis of JAK/STAT-signaling after co-treatment with MeV-GFP 
and resminostat 
“We then investigated the impact of resminostat on MeV‑GFP-
induced activation of IFN signaling in AsPC-1, BxPC-3, and PANC
‑1 cells. As a result, resminostat monotreatment did neither result 
in phosphorylation of STAT1 nor in expression of IFIT1. 
 
 
Figure 23: Resminostat does not impair MeV-induced activation of IFN 
signaling 
AsPC-1, BxPC-3 and PANC‑1 cells were mock-treated (mock), treated with 
resminostat (Res) or/and MeV‑GFP (MeV) or not treated at all (mock). 
Stimulation with IFN‑β for 24 h (IFN‑β) served as a positive control. MeV-induced 
activation of IFN‑signaling was revealed by phosphorylation of STAT1 (phospho-
STAT1) and expression of IFIT1, being detected by immunoblotting. β-actin was 
used as a loading control. 
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However, both MeV‑GFP infection alone as well as the epi-viro-
therapeutic combination resminostat plus MeV‑GFP were found to 
activate IFN signaling at both 72 and 96 hpi, indicated by 
phosphorylation of STAT1 and expression of IFIT1 (Fig. 23). As MIA 
PaCa-2 cells did not initiate IFN signaling after MeV‑GFP infection, 
we stimulated these tumor cells with IFN‑β (please note: BxPC-3 
cells were used as a control in this experiment). Some of these were 
additionally treated with resminostat. As a result, IFN‑β treatment 
was found to induce IFN signaling; but similar to all prior results, 
resminostat was unable to inhibit phosphorylation of STAT1 and 
expression of IFIT1 (Fig. 24). These results clearly imply that 
resminostat does not impair the IFN response of pancreatic cancer 
cells that had been initiated by infection with MeV‑GFP. 
Consequently, resminostat does not elicit synergistic effects due to 
an impairment of the anti-viral response. 
 
 
Figure 24: Resminostat does not impair IFN signaling in MIA PaCa-2 cells being 
exogenously stimulated by IFN 
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MIA PaCa-2 and BxPC-3 cells were treated with IFN‑β and/or resminostat (Res) for 24 h 
or not treated at all (mock). Potential impairment of IFN signaling by resminostat was 
deduced from phosphorylation of STAT1 (phospho-STAT1) and expression of interferon-
induced protein with tetratricopeptide repeats 1 (IFIT1). β-actin was used as a loading 
control.” (Ellerhoff et al., 2016) 
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4. Discussion 
“Oncolytic viruses have recently made a major move toward their 
full establishment in clinical practice by approval of Imlygic® both 
by the American Food and Drug Administration (FDA) and by the 
European Medicines Agency (EMA) (Ledford, 2015). In our study, 
an epi-virotherapeutic approach was pursued, augmenting 
oncolytic MeV with the oral HDACi resminostat. 
Both agents already have been evaluated independently as well as 
recently in combination for the treatment of different solid tumors 
with encouraging results (Russell et al., 2012, Nguyen et al., 2010, 
Ruf et al., 2015, Brunetto et al., 2013, Abend and Kehat, 2015, 
Mottamal et al., 2015, Feng et al., 2014, Xu et al., 2013). Here, we 
tested a series of four human pancreatic cancer cell lines: i) for their 
sensitivity to both agents in monotreatment and subsequently ii) 
toward the effect of epi-virotherapeutic co-treatment. 
At the outset, monotreatment experiments revealed that both 
agents, oncolytic MeV‑GFP as well as resminostat, caused dose- 
and time-dependent tumor cell killing in all tested human pancreatic 
cancer cell lines. Strikingly, the cytotoxic effect of resminostat on a 
specific cancer cell line could not be predicted from the results 
obtained in OV cytotoxicity assays and vice versa. This is most 
clearly visible when comparing the virotherapeutic with the 
epigenetic results obtained with PANC‑1 cells emphasizing that 
there is no cross-resistance between OV and other cytotoxic drugs 
such as HDACi. 
Subsequently, cooperative effects were evaluated by performing 
SRB cell viability assays and afterwards confirmed utilizing the 
xCELLigence system. The results showed that the epi-
virotherapeutic approach elicited beneficial cytotoxic effects in all 
four pancreatic cancer cell lines. Regarding MIA PaCa-2 tumor 
cells, considerable synergistic results were observed: virus-
mediated reduction in the tumor cell masses was found to be 
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improved in the presence of resminostat from 35 to 81% (at MOI 
2.5) as well as from 55 to 92% (at MOI 5) (Fig. 17). Similarly, epi-
virotherapeutic treatment of the other three cancer cell lines 
exhibited stronger effects than obtained in monotreatment. In 
further experiments we found that virus growth curves revealed no 
significant differences in the presence or absence of resminostat, 
suggesting that resminostat neither facilitated virus entry nor 
enhanced virus replication. 
With regard to studies that have already investigated the 
therapeutic potential of epi-virotherapeutic treatment of different 
tumor entities, the most frequently examined and highlighted 
molecular mechanism of synergism is the ability of HDACi to impair 
the anti-viral immune response of host tumor cells, thereby 
facilitating virus replication and spread. Many underlying 
mechanisms have been revealed, describing involvement of HDAC 
activity in almost each step of IFN signaling. Virus infection leads to 
phosphorylation of IFN‑regulatory factors (IRFs), homo- or 
heterodimerization and translocation into the nucleus where IFN‑β 
expression is induced (Honda et al., 2006). Trichostatin A (TSA) 
was shown to prevent proper IRF-3 function, thereby hindering cells 
to produce IFN‑β (Nusinzon and Horvath, 2006). Downstream 
signaling of the IFN‑β receptor likewise requires HDAC activity, 
enabling proper receptor activation, STAT dimerization, and IRF-9 
function as well as the formation of the IFN‑stimulated gene factor-
3 (ISGF3) (Genin et al., 2003, Tang et al., 2007, Yuan et al., 2005). 
Also, HDAC are involved in the expression of IFN‑stimulated-genes 
(ISGs) (Chang et al., 2004). Accordingly, HDAC inhibitors were 
proven to impair the expression of ISGs when tumor cells were 
coincidently infected with oncolytic viruses (Otsuki et al., 2008, 
Shulak et al., 2014, Nguyen et al., 2008). Due to these findings, the 
enhanced oncolytic effect was retrospectively assigned to the 
interference with IFN signaling. 
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In contrast to these observations, the present epivirotherapeutic 
approach did not modulate IFN signaling as indicated by an un-
altered phosphorylation of STAT1 and expression of the ISG IFIT1 
in any of the tested pancreatic cancer cell lines. Moreover, no 
obvious alteration in virus growth kinetics could be observed. For 
these reasons, our experiments do not support the prevailing 
opinion of HDACi damping the IFN‑response thus enhancing OV-
mediated oncolysis. In respect of implementing our epi-
virotherapeutic approach into clinical practice, it is potentially even 
not preferable that type I IFN production is impaired. Since 
especially IFN‑α and IFN‑β are essential cytokines that attract and 
prime cytotoxic and T helper cells by causing expression of 
important receptors on cancer cells (such as MHC I), type I IFN 
secretion from tumor sites might amplify an antitumor immune 
response (Fuertes et al., 2011, Prestwich et al., 2009).  
Other studies having examined the potential of HDACi to enhance 
different virotherapeutics obtained similar findings. After having 
infected different infection-resistant cancer cells with vaccinia virus 
(VV) that had retained their B18R gene, functioning as an IFN 
antagonist, the HDACi TSA was still capable of amplifying OV-
mediated oncolysis, suggesting that its antitumor effect was not 
based on an immunosuppressive function (MacTavish et al., 2010). 
In our study, MIA PaCa-2 was the only pancreatic cancer cell line 
which did not exhibit an activation of the IFN signaling pathway after 
MeV infection. Despite this lack of establishing a proper anti-viral 
state, it was not the most susceptible cell line to MeV-mediated 
oncolysis and more noteworthy, epi-virotherapeutic treatment 
showed the most pronounced effect in this cell line, stressing that 
HDACi seem to enhance virus-mediated oncolysis by eliciting other 
effects than damping the IFN response. This raises the question 
which additional mechanisms could explain the enhancement of 
virus-mediated cell death by epi-virotherapeutic co-treatment. 
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Explanations, amongst others, were provided by Liu et al (Liu et al., 
2008). Using an epi-virotherapeutic approach consisting of 
oncolytic herpes-simplex-virus (HSV) and TSA in a panel of tumor 
and normal quiescent cells, they obtained beneficial cytoreductive 
effects compared to monotreatment. These effects could be 
attributed neither to the dosing schedule nor to enhanced infectivity 
or virus replication. The authors rather ascribed the results to a 
decrease in expression of cyclin D1, mediating cell cycle arrest, and 
VEGF, reinforcing the hypothesis of vascular shutdown induced by 
OV (Breitbach et al., 2011). 
Beyond the above, further replication-independent mechanisms 
have been illustrated, highlighting the impact of HDACi on cell 
signaling. Thus, HDACi cause hyperacetylation of NF-κB, thereby 
increasing its nuclear retention and DNA binding capacity. Due to 
its promotion of HSV gene expression, this HDACi-mediated effect 
elicited synergistic tumor killing in oral squamous cell carcinoma 
(SCC) cells (Katsura et al., 2009). Furthermore, combined 
treatment was shown to increase the expression of p21 which 
mediates cell cycle arrest, consequently slowing down tumor 
progression and resulting in the induction of tumor cell apoptosis. 
Recently, Shulak et al found a mechanism explaining NF-κB activity 
accompanied by an enhanced OV-mediated oncolysis. They 
pointed out that hyperacetylation and nuclear retention of NF-κB 
induced the expression of several autophagy-related genes. They 
argued that the induction of autophagy led to an impairment of IFN 
signaling but also to vesicular stomatitis virus (VSV)-mediated 
apoptosis in prostate cancer cells (Shulak et al., 2014). Autophagy 
is a process that is per se frequently enhanced in tumor cells since 
it serves as a stress response to oxidative stress, lack of nutrients, 
and hypoxia as it is commonly present in the microenvironment of 
solid tumors (Murrow and Debnath, 2013). Interestingly, pancreatic 
cancer cells even require this catabolic process in order to prevent 
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accumulation of ROS, thereby contributing to tumor growth as well 
as establishing the basis for drug resistance (Yang et al., 2011, 
White and DiPaola, 2009)(64,65). Despite these pro-survival 
aspects, some viruses are notably capable of exploiting the 
autophagic machinery for the purpose of efficient replication (Dreux 
and Chisari, 2010). Attenuated MeV derived from the Edmonston 
strain actually induce and require autophagy for efficient replication 
(Richetta et al., 2013). Since hydroxamic acid based HDACi equally 
increase autophagic activity (Gammoh et al., 2012), it is tempting to 
speculate that the effect elicited by resminostat in combination with 
oncolytic MeV is caused by an enhanced self-digestion and 
subsequently enhanced tumor cell death. 
Physiologically, cell signaling often requires protein modifications 
such as phosphorylation or acetylation but beyond targeting cell 
proteins, even pathogenic proteins can serve as substrates for 
those modifications, resulting either in enhanced or impaired 
activity. In this context, it was revealed that a portion of the NS-1 
protein, representing the major pathogenic and most important 
protein for replication of the rat parvovirus H-1PV, gets acetylated 
during virus infection (Hristov et al., 2010). Noteworthy, treatment 
with VPA caused hyperacetylation of NS-1 resulting in an 
accumulation of ROS and an enhanced transcriptional activity. 
Ultimately, DNA damage in cancer cells was observed 
consequently inducing apoptosis. Those findings were confirmed 
later in vivo, resulting in complete disappearance of implanted 
tumors in mice that had undergone co-treatment with H-1PV and 
VPA (Li et al., 2013). Likewise, HDACi-related hyperacetylation of 
microtubules accelerated nuclear translocation of oncolytic HSV-
genomes, thereby enhancing the antitumor effect in glioma stem-
like cells (Nakashima et al., 2015a). 
In conclusion, our results provide evidence that the epivirothera-
peutic combination of oncolytic MeV and the HDACi resminostat 
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constitutes a beneficial option in the treatment of advanced 
pancreatic ductal adenocarcinoma. We revealed an augmentation 
of MeV-mediated oncolysis by resminostat. Treatment of MIA 
PaCa-2 cells resulted even in a synergistic enhancement of the 
tumor-killing potential when compared to the monotherapies. 
Molecular mechanisms underlying the synergistic effects and the 
potential of our epi-virotherapeutic approach in vivo have to be 
elucidated in animal models in the future.” (Ellerhoff et al., 2016) 
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5. Summary 
Since the beginning of the 19th century researchers have tried to 
cure cancer patients with the aid of virus infection. Due to the 
present developments of genetic modifications with the possibility 
of generating a specific tumor tropism and the clinical establishment 
of the first oncolytic virus, the field of virotherapy is of great interest. 
To overcome existing limitations of virotherapeutics and to further 
enhance the antitumor efficiency of oncolytic viruses, the present 
study was conducted to examine the therapeutical potential of an 
epi-virotherapeutic approach combining oncolytic measles virus 
with the oral Histone-Deacetylase-Inhibitor resminostat on a panel 
of human pancreatic cancer cell lines. 
After having determined the antitumor potential of each agent in 
monotreatment, SRB cell viability assays revealed that epi-vio-
therapeutic treatment elicited much stronger cytotoxic effects than 
single-agent treatment on the four human pancreatic cancer cell 
lines. Those were partly stronger than those that would be 
statistically expected from an additive effect. 
These results were subsequently confirmed and specified by 
performing real-time tumor cell proliferation assays (xCELLigence). 
Preparation and analysis of virus growth curves showed that virus 
replication and spread exhibited similar growth kinetics regardless 
of whether resminostat had been additionally applied or not. 
Furthermore, analysis of the surrogate parameter zfp64 confirmed 
that resminostat is not impaired in its pharmacodynamic function in 
human pancreatic cancer cells that had been infected with measles 
virus. 
The most highlighted molecular synergistic working point is the 
ability of HDACi to impair the antiviral immune response of cancer 
cells leading to enhanced virus replication and consequently to 
enhanced virus-mediated oncolysis. In contrast, our immunoblot 
analysis of the resminostat-based modulation of virus-induced IFN-
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signaling activation, represented by phosphorylation of STAT1 and 
the expression of IFIT1, revealed no difference whether human 
pancreatic cancer cells had been treated additionally with 
resminostat or not. 
In conclusion, our data show that epi-virotherapeutical treatment of 
human pancreatic cancer cells is beneficial when compared to 
either of the mono-agent treatments. Furthermore, it is suggested 
that oncolytic measles and resminostat seem to act independently. 
Future studies should investigate the anti-tumoral potential of the 
epi-virotherapeutic approach in vivo which should also serve to find 
underlying molecular mechanisms of synergy. 
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6. Zusammenfassung 
Bereits zu Beginn des 19. Jahrhunderts versuchten Wissen-
schaftler Tumorpatienten mithilfe von Virusinfektionen zu heilen. Im 
Zuge der Möglichkeit, Viren genetisch zu modifizieren, einen 
definierten Tumortropismus zu erzeugen und der aktuell erfolg-
reichen Anwendung an Patienten mit malignem Melanom erlangte 
das Forschungsfeld der Virotherapie in den letzten Jahren großes 
Interesse. 
Die vorliegende Studie wurde durchgeführt, um bestehende 
Limitationen der Virotherapie zu adressieren und weiterhin die anti-
tumorale Effizienz onkolytischer Viren zu verbessern. Der dabei 
gewählte Ansatz bestand aus einer Kombination von onkolytischen 
Masern-Impfviren und dem oral applizierbaren Histon-Deacetylase-
Inhibitor (HDACi) Resminostat, welcher auf seinen anti-tumoralen 
Effekt an vier verschiedenen humanen Pankreaskarzinomzelllinien 
untersucht wurde. 
Nachdem zunächst das zytoreduktive Potential jedes einzelnen 
Kombinationspartners untersucht worden war, zeigten die SRB 
Zellviabilitäts-Assays, dass der epi-virotherapeutische Ansatz in 
allen vier humanen Pankreaskarzinomzelllinien dem jeweiligen 
Monotherapie-Ansatz überlegen war. Die anti-tumoralen Effekte 
waren dabei sogar zum Teil stärker als es statistisch für einen rein 
additiven Effekt zu erwarten gewesen wäre. 
Im Anschluss wurden die Ergebnisse mithilfe des Echtzeit-mes-
senden Zell-Proliferations-Assays xCELLigence bestätigt und hin-
sichtlich des gesamten Behandlungszeitraumes genauer analy-
siert. Die Viruswachstumskurven zeigten keinen statistisch 
signifikanten Unterschied, unabhängig davon, ob die humanen 
Pankreaskarzinomzellen zusätzlich mit Resminostat behandelt 
worden waren oder nicht. 
Weiterhin konnte gezeigt werden, dass der Surrogat-Parameter 
zinc-finger-protein 64 (zfp64) nach Resminostatbehandlung sowohl 
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in unifizierten wie infizierten Pankreaskarzinomzellen vermindert 
exprimiert wurde, womit die uneingeschränkte pharmako-
dynamische Funktion bewiesen werden konnte. 
Ein Effekt von HDACi, der als grundlegend für den epi-
virotherapeutischen Ansatz eingestuft wird, besteht in der 
Hemmung viraler Abwehrmechanismen der Tumorzellen (v.a. IFN-
induziert). Im Gegensatz dazu zeigten die Untersuchungen des 
JAK-STAT-Signalweges (exemplarisch ermittelt durch den Nach-
weis der Phosphorylierung von STAT1 und der Expression von 
IFIT1), dass in den infizierten humanen Panreaskarzinomzellen 
keine Resminostat-basierte Modulation der IFN-Antwort stattfand. 
Zusammenfassend kann angenommen werden, dass die beiden 
Kombinationspartner überwiegend unabhängig voneinander 
wirken. In einem nächsten Schritt gilt es nun, diese Wirk-
mechanismen in vivo zu untersuchen und darüber hinaus weiter an 
der Aufklärung der zugrundeliegenden Mechanismen der epi-
virotherapeutischen Effizienzverstärkung zu arbeiten. 
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7.3. List of abbreviations 
5-FU 5-fluorouracil 
ANOVA analysis of variance 
APC antigen-presenting cells 
APS ammonium persulfate 
BSA bovine serum albumin 
CAR coxsackie- and adenovirus receptor 
CD Cluster of differentiation 
CDV canine distemper virus 
CPE cytopathic effect 
CSF colony-stimulating factor 
CTCL cutaneous T-cell lymphoma 
CTLA-4 cytotoxic T-lymphocyte-associated protein 
4 
DC dendritic cell 
ddH2O double-distilled water 
DMEM Dulbecco’s modified eagle’s medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DSMZ german collection of microorganisms and 
cell cultures 
ECACC european collection of authenticated cell 
cultures 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EGFR-TKI epidermal growth factor receptor tyrosine 
kinase inhibitor 
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ELISA enzyme-linked immunosorbent assay 
FCS fetal calf serum 
FDA food and drug administration  
GFP green fluorescent protein 
GM-CSF Granulocyte-macrophage colony-
stimulating factor 
GTP guanosine triphosphate 
HAT histone acyltransferase 
HCAC histone deacetylase 
HCC hepatocellular carcinoma 
HIF hypoxia-inducible factor 
hpi hours post infection 
hpt hours post treatment 
HSV Herpes simplex virus 
IFIT1 interferon-induced protein with 
tetratricopeptide repeats 1 
IFN interferon 
IRF interferon regulatory factor 
ISG interferon-stimulated-gene 
KDAC lysine deacetylase 
MeV measles virus 
MHC major histocompatibility complex 
MMP matrix metalloproteinase 
MOI multiplicity of infection 
NF-κB nuclear factor kappa-light-chain-enhancer 
of activated B cells 
NIS sodium/iodide symporter 
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NK natural killer (cell) 
OV oncolytic virus 
PAMP pathogen-associated molecular patterns 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDAC pancreatic ductal adenocarcinoma 
PDAC protein deacetylase 
PD-L1 Programmed death-ligand 1 
PFU plaque-forming unit 
PVDF polyvinylidene difluoride 
PRR pattern-recognition-receptor 
PSCA prostate stem cell antigen 
PTCL peripheral T-cell lymphoma 
RIG-I retinoic acid inducible gene I 
RNA ribonucleic acid 
ROS reactive oxygen species 
RPV rinderpest virus 
SCD super cytosine deaminase 
SDS sodium dodecyl sulfate 
SLAM signaling lymphocyte activation molecule 
SRB sulforhodamine B 
STAT signal transducer and activator of 
transcription 
TAA tumor associated antigen 
TCA trichloroacetic acid 
TCID tissue culture infective dose 
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TEMED tetramethylethylenediamine 
TRAIL tumor necrosis factor related apoptosis 
inducing ligand 
TRIS Tris(hydroxymethyl)aminomethane 
VEGF vascular endothelial growth factor 
VPA valproate  
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